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Résumé 
Bien que l'efficacité des traitements pour réduire l'anxiété est bien documentée dans le 
cas de la phobie sociale, la recherche considère peu le processus de réduction d'anxiété 
comme tel pendant le traitement. De plus, peu d'études comparent la combinaison d'une 
approche psychologique et pharmacologique pour le traitement de la phobie sociale. C'est que 
la présente recherche se propose de faire. L'étude compare l'efficacité d'une thérapie 
d'approche interpersonnelle seule à une thérapie d'approche interpersonnelle combinée à la 
paroxetine chez les phobiques sociaux durant 12 séances de traitement. Les participants de 
cette étude se composent de 30 hommes et 18 femmes adultes recrutées au Centre de 
Recherche Fernand-Seguin (CRFS) de l'Hôpital Louis-H.-Lafontaine de Montréal. Les 
mesures principales d'anxiété sont l'Échelle d'anxiété et d'évitement social (Social Anxiety 
and Distress Scale-SAD) et l'Échelle de peur (Fear Questionnaire-FQ). Les résultats de cette 
étude confirment l'hypothèse selon laquelle le traitement combiné est plus efficace et stable 
pour réduire l'anxiété durant les 12 sessions. Les conclusions de cet mémoire permettent de 
mieux comprendre la valeur ajoutée d'une approche pharmacologique dans le traitement de la 
phobie sociale ainsi que de définir le cadre théorique d'un traitement combiné. 
Most clés: réduction anxiété, phobie sociale, anxiété sociale, paroxétine, thérapie 
interpersonnelle, traitements combinés. 
IV 
Abstract 
Although a substantial amount of evidence exists for the reduction of anxiety levels in 
the various treatments for social phobia, there has been less interest in the actual process of 
anxiety reduction during the treatment phase itself. Moreover, few studies on social phobia 
have combined psychological and pharmacological treatments to investigate the process of 
therapeutic change. The present study aims to bridge these gaps by comparing an 
interpersonal approach to therapy and an interpersonal approach to therapy combined with 
paroxetine in a 12 week treatment and outline which treatment best reduces anxiety in that 
time span. Participants were 30 adult males and 18 females recruited through the Centre de 
Recherche Fernand~Seguin (CRFS) at the L.H. Lafontaine Hospital in Montreal. Anxiety was 
measured by means of the Social Anxiety and Distress scale as weB as the Fear 
Questionnaire. It is hypothesized that the combined approach wiB be a superior treatment both 
during the process of therapy as weil as at post~treatment. Results indicate that the combined 
approach reduce anxiety in a more efficient and stable manner during the 12 sessions. These 
results add valuable knowledge into the contribution of medication to the treatment of social 
phobia and the conceptual framework behind the combined treatment approach. 
Key words: anxiety reduction, social phobia, social anxiety, paroxetine, interpersonal 
approach to therapy, combined treatment. 
v 
Table of contents 
Résumé .................................................................................................... .iii 
Abstract .................................................................................................... .iv 
Table of contents .......................................................................................... v 
List of tables ............................................................................................... vii 
List of figures ............................................................................................ vix 
List of abbreviations ...................................................................................... x 
Acknowledgements ...................................................................................... xi 
Introduction ................................................................................................ 1 
1.1. Social Phobia ................................................................................. 1 
1. 2. Treatments for social phobia .............................................................. 2 
1.3. CombinedlCompared Treatments .......................................................... 5 
lA. Psychological Treatments ................................................................... 9 
1.5. Pharmacological Treatments .............................................................. 14 
1.4. Current study ........................................................... ~ ................... 18 
Method .................................................................................................... 20 
2.1. Participants ................................................................................. 20 
2.2. Exclusion criteria .......................................................................... 21 
2.3. Assessment ................................................................................. 24 
204. Self-reports: Subjective anxiety ......................................................... 24 
2.5. Treatment. .................................................................................. 26 
2.6. The interpersonal approach ............................................................... 27 
2.7. Combined group ............................................................................. 28 
2.8. Dosage ...................................................................................... 29 
Results ..................................................................................................... 32 
3.1. Participation rates .......................................................................... 32 
3.2. Descriptive statistics ....................................................................... 34 
3.3. F correction ................................................................................. 34 
304. Test ofEquality ofVariance-Covariance .............................................. 37 
3.5. Inferential statistics ........................................................................ 37 
Subsequent analyses 
4.1. Effect size measure ........................................................................ 41 
vi 
4.2. Pairwise comparisons ..................................................................... 43 
4.3. Trend analysis .............................................................................. 44 
Discussion ................................................................................................ 52 
5.1. Conclusions ................................................................................. 52 
5.2. Theoretical conclusions ................................................................... 56 
5.3. Findings and SP literature ................................................................ 59 
5.4. Strengths and limitations ................................................................... 60 
5.5. Future directions ........................................................................... 61 
References ................................................................................................ 65 
Appendices ............................................................................................... xii 
6.1. Appendix 1: Telephone interview script.. .............................................. xii 
6.2. Appendix II: SAD ......................................................................... xiv 
6.3. Appendix III: FQ .......................................................................... xvi 
6.4. Appendix IV: Consent form .............................................................. xvii 
6.5. Appendix V: Paroxetine administration protocol table ................................ xx 
6.6. Appendix VI: Pairwise comparisons .................................................... xxi 
6.7. Appendix VII: Trend analysis ........................................................... xxvii 
6.8. Appendix VIII: Sample trend graphs ................................................... xxx 
V1l 
List of tables 
Table 1: Means (and standard deviations) of demographic and clinical characteristics 
of the sample ............................................................................................. 22 
J 
Table II: Demographic and clinical characteristics of the sample .................................. 23 
Table III: Paroxetine dosage in the combined condition ............................................ 30 
Table IV: Means (and standard deviations) of the SAD Total scores of the sample ............ 35 
Table V: Means (and standard deviations) of the SAD Avpidance subscale scores 
of the sample ............................................................................................ 35 
Table VI: Means (and standard deviations) of the SAD Distress subscale scores of 
the sample ............................................................................................... 35 
Table VII: Means (and standard deviations) of the FQ Composite scores of 
the sample ............................................................................................................................. 36 
Table VIII: Means (and standard deviations) of the FQ Social Phobia subscale scores 
of the sample ........................................................................................... 36 
Table IX: Means (and standard deviations) of the FQ Emotional Distress subscale 
scores of the sample ................................................................................... 36 
Table X: Statistical significance of anxiety and distress measure across time 
and treatment group .................................................................................. 38 
Table XI: Significant pairwise comparisons oftime for the SAD total scores of the 
sample .................................................................................................. xxi 
Table XII: Significant pairwise comparisons oftime for the SAD Avoidance 
scores of the sample ................................................................................... xxii 
Table XIII: Significant pairwise comparisons oftime for the SAD Distress scores 
of the sample ........................................................................................... xxiii 
Table XIV: Significant pairwise comparisons oftime for the FQ Composite scores 
of the sample ........................................................................................... xxiv 
Table XV: Significant pairwise comparisons oftime for the FQ Social Phobia 
scores of the sample ................................................................................... xxv 
Table XVI: Significant pairwise comparisons oftime for the FQ Emotional Distress 
scores of the sample ................................................................................. xxvi 
viii 
Table XVII: Statistical significance of Iinear trend analysis across time and treatment 
condition ................................................................................................ xxvii 
Table XVIII: Statistical significance of quadratic trend analysis across time and treatment 
group ................................................................................................... xxvii 
Table XIX: Statistical significance of cubic trend analysis across time and treatment 
group ................................................................................................... xxix 
vix 
List of figures 
Figure 1: Mean dosage of patients in the combined condition across time ..................... 31 
Figure 2: Flow chart of the study ..................................................................... 33 
Figure 3: Mean scores of the SAD Total scale across time and condition ....................... 46 
Figure 4: Mean scores of the SAD Avoidance subscale by treatment group across time ...... 47 
Figure 5: Mean scores of the SAD Distress subscaleby treatment group across time ......... 48 
Figure 6: Mean scores ofthe FQ Composite score by treatment group across time ........... 49 
Figure 7: Mean scores of the FQ Social Phobia subscale by treatment group across time ... 50 
Figure 8: Mean scores of the FQ Emotional Distress subscale by treatment group across 
time ......................................................................................................... 51 
Figure 9: Sample linear trend graph .................................................................. xxx 
Figure 10: Sample quadratic trend graph ........................................................... xxxi 
Figure Il: Sam pIe cubic trend graph ................................................................ xxxii 
List of abbreviations 
AOIS-R: Anxiety disorders interview schedule 
CBGT: Cognitive behaviour group therapy 
CBT: Cognitive behaviour therapy 
CR : Cognitive restructuring 
CRFS: Centre de Recherche Fernand-Seguin 
DSMV-IV: Diagnostic and Statistical Manual of Mental Disorders 
FQ: Fear questionnaire 
GABA: Gamma-aminobutyric acid 
MAOI: Monoamine oxidase inhibitors 
M.G.: Milligram 
N.S.: Not significant 
OCD: Obsessive-compulsive disorder 
SAD: Social anxiety and distress scale 
S.O.: Standard deviation 
SNRI: Serotinin-norepinephrine reuptake inhibitors 
SP: Social phobia 
SSRI: Selective reuptake inhibitors 
SST: Social skills training 
RIMA: Reversible inhibitors of monoamine oxidase 
x 
Xl 
Acknowledgements 
1 would fist like to thank my supervisor, Dr. Ariel Stravynski, for his immeasurable 
contribution to this work. His knowledge, expertise, time and support have made this possible. 
1 would also like to thank Lise Lachance for her statistical help and Danielle Amado for her 
guidance and advice. 
My thanks also goes out to aIl my close supporters who have each in their own way 
encouraged and sustained me throughout this endeavour. 
Introduction 
Social phobia 
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) identifies social 
phobia (SP) or social anxiety as the experience of fear and anxiety in social situations and of 
being evaluated by others while impairing the social functioning of the individual (American 
Psychiatric Association, 1994). As defined, SP can be limited to a particular social situation (non-
generalized), such as meetings with coworkers, or encompass broader social contexts, known as 
generalized social phobia. However, the manual offers criteria for identifying SP rather than 
defining it. SP is a diffuse amalgamation of behaviours not easy to pin down in a definition. 
According to Stravynski (2007, p. 13): 
"[ ... ] social phobia is simultaneously an inordinate fear of humiliation resulting 
from public degradation that one is powerless to prevent [ ... ] as weIl as a 
comprehensive defensive interpersonal pattern [ ... ] protective against the threat of 
being treated hurtfully by others." 
While Stravynski views SP as both a fearful or anxious state as weIl as a complex 
interpersonal pattern, other sources (e.g.: pharmacological, cognitive) view it as a purely anxiety 
state, which has implications for treatment. For example, the pharmacological treatment of SP 
implies that it is an anxious disorder in which medication would eliminate the anxiety and thus 
'cure' SP. However, the results ofsuch treatments are not without shortcomings (i.e.: serious 
undesirable effects). As such, SP is a much more complicated and elusive pattern ofbehaviours. 
SP is a serious and long-lasting pattern. A longitudinal study by Yonkers, Dyck and 
Keller (2001) revealed that after a combined treatment of various psychotherapies and 
medication, 68% of social phobics continued to display problematic patterns of social functioning 
and 28% continued to fulfill the criteria of social phobia. This study shows that SP is a chronic 
problem and few seek out treatment. As for the prevalence of SP, depending on which source 
used, 7% to 13% of the North-American population me et the defining criterion (Sarason, 2007). 
SP is associated with significant problems, which can inc1ude limited social network, a1cohol 
abuse, little or no advancement at work or even abandoning a career to choose a less socially 
involved occupation (Stein & Kean, 2000). 
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This chronic and debilitating pattern has spurted a wave of studies for its treatment in the 
last decades. Although new developments in drug therapies and psychological treatments took 
place as of the 1980's, the combined effect ofpsychotherapy and medication has been little 
investigated. Furthennore, most studies on SP treatment have focused on the outcome of different 
treatments but few have investigated the process oftherapeutic change of anxiety. 
Hence, the present study aims to monitor participants' psychosocial state during a 
treatment plan in order to c1arify this process. However, before engaging in such an endeavor, it 
is imperative to review the main treatments used for SP. The next section will outline these 
treatments. 
Treatments for social phobia 
Treatments of social phobia have pursued two major strategies: the reduction of anxiety 
and the improvement of social functioning (Stravynski, 2007, pp. 291). For the scope of this 
study, l shaH focus the process of anxiety reduction in social phobics. 
For reducing anxiety in social phobia, the main psychological treatments used are 
exposure and cognitive restructuring. Exposure as a treatment is based on the principle that 
repeated and prolonged exposure to the feared stimuli will reduce the anxiety and fear related to 
being faced with such a threat (Marks, 1987. pp. 457-494). The person is induced to face the 
feared stimuli during the sessions until the level of distress is reduced to a tolerable level. 
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Cognitive restructuring (CR) rests on the theory that maladaptive beliefs or thoughts lead 
to erroneous thinking which generate anxiety (Beck, 1976). Using this assumption, this treatment 
attempts to identify and question distorted thinking (e.g.: exaggerations, ignoring counter-
evidence) of the participant during their discussion with the c1inician until he or she adopts more 
logical thoughts. This type of treatment combined with exposure is commonly referred as 
cognitive behaviour therapy (CBT). 
Social skills training (SST) is an alternative treatment that focuses on improving the 
social skills of the individual rather than focusing on reducing anxiety. Participants are taught 
generic social skills su ch as conversation techniques, assertive body language, eye contact 
through role rehearsal and modeling. They then apply the new skills to real-life situations 
between sessions. This latter part of the treatment is exposure-based. This structural approach, in 
its theoretical framework, is rooted in the recognition of the social inadequacy of social phobic 
individuals in their functioning in social situations (Stravynski, 2007, pp. 299-300). 
The types of treatments considered thus far regard social phobia as an intrapersonal 
difficulty, resulting in sorne inner quality of the person. A differing view of social phobia 
considers its nature interpersonally, as a way of dealing with the social environment. An 
interpersonal approach to therapy focuses on the functional aspect of social behaviour 
(Stravynski, Arbel, Chenier, Lachance, Borgeat, Lamontagne, Sidoun & Todorov, 2006). Instead 
of viewing social anxiety as stemming from the individual, the interpersonal approach assumes 
that social phobia is a collection of self-protective patterns used defensively during interactions. 
The social phobic, as opposed to a normal individual, will overextend these otherwise normal 
fearful tactics in social settings. Thus, the interpersonal approach " ... construes social anxiety 
relationally, [ ... ] evoked by social transactions ... " (Stravynski, 2007, pp. 300). Rather than 
correcting deficits skills or erroneous thoughts, the interpersonal approach provides social 
phobics with non-defensive, participatory, individualized methods to use in such situations. 
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The pharmacological approach, like CR and exposure, seeks to treat SP by attempting to 
reduce anxiety, thus it defines SP as a purely anxiety state. Four different classes ofmedication 
have been used thus far in the treatment ofSP (for more details see Stravynski, 2007, Chapter 10, 
pp. 305). Monoamine oxidase inhibitors (MAOI) act by preventing the breakdown of the brain 
chemical or neurotransmitter, monoamine, thereby increasing the available stores (e.g: 
phenelzine). A newer and preferred version ofthis class ofmedication, reversible inhibitors of 
monoamine oxidase (RIMAs), does not permanently interrupt the breakdown ofmonoamine 
(e.g.: moclobemide). 
Selective reuptake inhibitors (SSRIs) increase the level of the neurotransmitter serotonin 
available (e.g: paroxetine, fluoxamine, sertraline, citalopram). SSRIs are frequently prescribed to 
treat depression and anxiety disorders because they have less adverse effects and are better 
tolerated than MAOIs/RIMAs (Scott & Heimberg, 2000). Serotinin-norepinephrine reuptake 
inhibitors (SNRIs), in contrast to SSRIs, increase the levels of serotinin and norepinephrine as 
weIl (e.g.: venlafaxine). 
Benzodiazepines are a class of drugs that act on the neurotransmitter gamma-aminobutyric 
acid (GABA). They are considered min or tranquilizers that have sedative and muscle relaxant 
propreties (e.g: clonazepram). They are used to treat anxiety, insomnia, seizures and muscle 
spasms. Finally, anticonvulsants such as gabapentin and pregabalin are related to GABAs as well. 
They are used as mood stabilizers and to treat seizures. 
Knowing what the main SP treatments entail, the aim of the next sections will be to 
review and compare the existing treatments for SP and determine the process of anxiety reduction 
during therapy for each one. 
Combined/Compared Treatments 
Since a combination treatment for SP is of interest to the present investigation, the 
conclusions from past combination treatments will be reviewed. What can the existing literature 
tells us about the pro cess of anxiety reduction when psychological and pharmacological 
treatments are integrated? In this section, studies that have either compared or combined such 
approaches will be evaluated. 
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In terms of outcome results of combination treatments, Stravynski's review (2007) 
provides the following conclusion: "The combination ofpsychological treatments and medication 
... did not exceed the effects ofpsychological approaches alone."(Chapter 10, pp. 327-328). It 
seems a combination treatment is not necessarily a more effective treatment for SP. However, 
during the actual process oftreatment, how does a combination treatment fare in reducing anxiety 
compared to a pure psychological or pharmacological method? 
In one study examining the efficacy ofphenelzine (a RIMA) and CBT in group form, 
self-report questionnaires of anxiety and avoidance behaviours were administered at mid-
treatment (week 6) and at the end of treatm ent (week 12). For both experimental conditions, the 
process of anxiety reduction was equivalent. Anxiety levels decreased quite a bit from pre-
treatment to week 6, but less so from week 6 to 12. (Heimberg, Liebowitz, Hope, Schneier, HoIt, 
Welkowitz, Juster, Campeas, Bruch, Cloitre, Fallon & Klein, 1998). 
For the comparison of clonazepram (a benzodiazepine) and CBT, Otto, Pollack, Gould, 
W orthington, McArdle and Rosenbaum (2000) found that from the beginning of treatment to 
week 12, both experimental conditions reported scores that decreased linearly. Interestingly, 
between week 4 and 12, the medicated condition reported an increase in scores. Between week 12 
and the end of treatment, both experimental conditions reported slightly increased scores. An 
increase in anxiety during treatment seems counterintuitive; the purpose of receiving treatment 
would be to decrease anxiety rather than increasing it. This phenomenon in the management of 
anxiety would be interesting to investigate further to determine ifindeed it is part of the process 
ofanxiety management in SP. 
As for the comparison of SSRIs with psychotherapies, one study compared fluoxamine, 
CBGT (cognitive group behaviour therapy), placebo, a combination offluoxamine and CBGT, 
and CBGT with placebo in a 14 week treatment. In this particular study, the process of 
therapeutic change was featured in more detail. AlI experimental conditions reported scores that 
decreased at a steady pace until the end oftreatment. From week 4 to 8, this trend tapered off 
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wh en aIl the groups, except the placebo group, produced similar results (Davidson, Foa, Huppert, 
Keefe, Franklin, Compton, Zhao, Connor, Lynch & Gaddle, 2004a). 
Another study evaluated the effectiveness of fluoxamine and CBT for 16 weeks (Clark, 
Ehlers, McManus, Hackmann, FenneIl, Campbell, Flower, Davenport & Louis, 2003). From the 
beginning to the end oftreatment, anxiety levels diminished linearly for aIl treatment groups. 
Between week 16 and the end of treatment, the scores of the CBT group did not diminish as 
drastically, but remained at equivalent levels. This stabilizing of anxiety levels at the end of 
treatment is another interesting occurrence that caIls for additional inquiries to detect ifit notjust 
an isolated event. 
A long-tenu study compared a MAOI, moclobemide, with CBGT and CBGT alone in a 6 
month treatment process (Prasko, Dockery, Horacek, Houbova, Kosova, Klaschka, Paskova, 
Praskova, Seifertova, Zalesky & Haschl, 2006). The three treatment groups reported decreasing 
linear anxiety scores from the beginning oftreatment until the 3rd month. After that, the scores 
did not decreasing as quickly, and for the combined group there was a minor increase in the 
reported scores at the 4th month. Towards the end oftreatment, the 5th and 6th month, the scores 
were more or less the same for aIl the treatment groups. 
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To summarize these findings, the anxiety reduction pro cess of either a purely 
pharmacological or psychological approach compared to a combined treatment is more or less the 
same. At the beginning of treatment until about mid-treatment, anxiety decreases steadily. 
Afterwards, anxiety levels plateau and remain constant. Aside from sorne exceptions where 
increases of anxiety were noted, the process follows a straightforward linear pattern with a 
quadratic trend by end of treatment. It would be interesting to see if a similar pattern arises with a 
combination treatment of SSRI and psychotherapy. 
Evidently, few combined treatments studies exist that detail the process of anxiety 
reduction for SP. In that case, what can studies on combination treatments for other anxiety 
disorders tells us? As with SP, there is little existing literature that focuses on the process of 
anxiety reduction. 
Sharp, Power, Simpson & Swanson (1996) conducted a three month investigation of 
fluoxamine combined with CR, CR and fluoxamine alone for panic disorder with agoraphobia. In 
general, all treatment groups displayed anxiety levels that decreased in a linear fashion. As for the 
efficacy of the treatments, at day 42, the combined treatment reported significantly lower anxiety 
scores than the medication or CR group. By the end oftreatment, the CR group reached the 
similar levels of anxiety with the combined group, significantly lower than the medication group. 
An earlier study used a benzodiazepine, alprazolam, and compared it to exposure for 38 
weeks (Marks, Swinson, Basoglu, Kuch, Noshirvani, Q'Sullivan, Lelliott, Kirby, McNamee, 
Seguin & Wickwire, 1993). The group taking alprazolam alone began to improve (diminishing 
anxiety scores) by the second week, plateaud at week 4 and thereafter the scores actually 
increased slightly. The group that received exposure treatment alone also improved as ofweek 2. 
As for the combined treatment group (alprazolam and exposure), therapeutic gains bega,n at week 
2. From week 8 to 18, the scores continued to diminish; afterwards they remained more or less at 
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those levels until the end oftreatment (week 38). The researchers concluded that alprazolam with 
exposure is not significantly better than alprazolam alone. 
Another anxiety disorder, obsessive-compulsive disorder (OCD), was examined to find if 
a combined treatment of clomipramine (a tricylic anti-depressant) and exposure was superior to 
single treatments in a 12 week period (Foa, Liebowitz, Kozak, Davies, Campeas, Franklin, 
Huppert, Kjemisted, Rowan, Schmidt, Simpson & Tu, 2005). The measures used in this study 
were based on OCD indicators of severity rather than anxiety measures. Both the combined group 
and exposure alone group had significantly lower scores than the clomipramine group from 
beginning of treatment to week 4. Between that time period, the trend in the reported scores 
appeared to be linear in nature for the treatment groups. From week 4 to the end of treatment 
(week 12), the scores remained more or less the same for aIl groups, with the combined group 
slightly outperfom1ing the exposure group. 
Bellino, Zizza, Rinaldi and Bogetto (2006) combined two treatments for major 
depression, fluoxamine and interpersonal therapy (for depression), and compared it to fluoxamine 
treatment alone in a 24 week study. Anxiety levels were assessed at three points during treatment, 
pre-treatment, at week 12 and at the end oftreatment (week 24). During aU the assessment points, 
the repOlied anxiety scores decreased linearly for both treatment groups. Specifically, anxiety 
levels for the phannacotherapy group were lower at mid-point and at the end of treatment, 
however not significantly so. 
In summary, in tenns of whether a combination treatment is more effective than a purely 
psychological or phannacological treatment, the results echo Stravynski's conclusions: neither is 
superior to the other. As for the process of anxiety reduction, it appears to foUows a linear 
pattem, no matter the approach. AIso, sorne studies showed that towards the end of treatment, 
anxiety scores level off and do not reduce anymore. These conclusions are limited because of the 
scarcity of process studies and the lack of detail when they do report the process; most studies 
only I11easured anxiety at three assessments during the whole treatment. 
Psychological treatments 
As demonstrated, there are not many combination treatment studies for anxiety disorders 
that follow the process of anxiety reduction. Consequently, l tum to studies on purely 
psychological treatments for SP to determine if there is any evidence on the said process. 
Firstly, based on Stravynski's (2007) exhaustive review on outcome studies, when CR 
and exposure are compared he concludes: "Clinically and practically, exposure, cognitive 
restructuring, and their combination as CBT [cognitive behaviour therapy] produced equivalent 
effects." (2007, Chapter 10, pp. 299). 
Therefore, even when exposure is compared to a combination of exposure and cognitive 
restructuring, it is no more effective. Since CBT has elements of exposure, as opposed to just a 
pure exposure treatment, it would be expected to reduce anxiety to a greater degree. However, it 
is no more effective th an the pure exposure treatment. Even when compared to non-specifie 
psychotherapies, such as applied relaxation (techniques ofmuscle relaxation) and task 
concentration (concentration exercises), cognitive restructuring produces similar improvements 
(Bogels, Sijbers, & Voncken, 2006). This begs the question of the usefulness of cognitive 
restructuring in reducing anxiety for social phobies. 
As for the structural approach of social skills training, Stravynski' s review found: [ ... ] 
this strategy to be as effective as exposure and cognitive restructuring in reducing anxiety and 
avoidance [ ... ). (2007, Chapter 10, pp. 304). Both SST and CBT do not seem to add any useful 
component to reducing social anxiety. As such, exposure can be regarded as a consistently 
effective treatment for reducing anxiety post-treatment. 
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A less common method to treating SP is the interpersonal approach to therapy. Although 
there are few studies that have investigated the interpersonal approach as a treatment for social 
phobia, the studies that have used it as an experimental group show that it is superior to.a waiting 
list and equivalent to a combination of SST and interpersonal approach to therapy or other non-
specific psychotherapies (Stravynski, Arbel, Bounader, Lachance, Borgeat, Lamontagne, Sidoun 
& Todorov, 2000; Stravynski et al., 2006). 
Although improvement in social functioning is the main goal of this treatment, the aspect 
of anxiety experienced by the participants is indirectly addressed as part of the treatment process. 
This can be seen in the reduction of avoidance behaviours and subjective distress. However, 
about 20-25% ofpmiicipants in that study abandoned therapybecause of the difficulty of 
managing anxiety during role-rehearsals and homework assignments practiced in real-life 
situations (Stravynski et al., 2000). 
From these studies, it is evident that anxiety reduction is an important part oftherapeutic 
change. Although outcome studies on anxiety reduction are extensively documented, little is 
known on the actual process of anxiety reduction and which psychological treatment is most 
effective at lessening anxiety during treatment. 
For that purpose, l first tum to Stravynski, Grey and Elie (1987) who conducted an 8 
week process study of the treatment of SP. In that study, each participant had a particular 
behavioural task to perforrn that promoted social participation (i.e.: introducing oneself, asking a 
question). This study showed that a relationship exists between anxiety and social functioning as 
measured in between sessions. As social functioning improved, social anxiety lessened. The 
anxiety reduction process followed a linear trend, meaning a steady decrease of anxiety was 
noted. However, towards week 3, the dec1ine in anxiety levels slowed down and stabilized, from 
a linear to a quadratic trend. As with combinations studies, this investigation of a psychological 
treatment found similar trends of a linear pattern at the beginning of treatment and a stabilizing 
effect towards the end. Would the same pattern be found ifthese psychologica1 and 
pharmacological treatments are compared and combined? 
In another study (Scholing & Emmelkamp, 1993), social avoidance was measured four 
times during the treatment process for three experimental groups: exposure, CBT and a 
combination ofboth. The pro cess of anxiety reduction for all the treatment groups followed a 
steady linear decrease but at the end of treatment it appears that the scores levelled off. 
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A more recent study compared two psychotherapies and assessed anxiety levels three 
times during treatment. For both treatments conditions, the decreasing anxiety scores followed a 
distinctly linear trend (Cottraux, Note, Albuisson, Yao, Note, Mollard, Bonasse, Jalenques, 
Guérin & Coudert, 2000). 
As in the combined treatment literature, there is a definite shortage ofresearch for the 
process of anxiety reduction of purely psychological approaches. Aside from these studies, little 
is known about the actual therapeutic process of anxiety reduction with various psychological SP 
treatments. For that reason, l shall widen the search to other anxiety disorders in an attempt to 
gain more infonnation on the anxiety reduction process. 
A study investigating the efficacy of CR for treating OCD versus exposure monitored 
anxiety levels during 16 weeks (Cottraux, Note, Yoa & Lafont, Mollard, Bouvard, Sauteraud, 
Bourgeois & Dartigues, 2001). From the beginning oftreatment to week 4, anxiety scores 
decrease linearly for both groups. However, from week 4 to 16 (end of treatment) , anxiety 
actually increased for both groups. Again, this increase in anxiety counters the expected effect of 
the treatment and invites further studying ofthis occurrence. Neither treatment was found to be 
more effective at reducing avoidance behaviours and subjective distress at a statistically 
significant level. 
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An earlier study conducted a similar investigation of OCD with the same treatments and 
number of sessions (van Oppen, de Haan, van Balkom, Spinhoven, Hoogduin & van Dyck, 
1995). Again, the difference in anxiety scores between the two treatments was not significant; 
however the diminishing scores followed a significant linear trend. 
In the treatment of panic disorder and agoraphobia, Bouchard, Gauthier, Laberge, French, 
Pelletier and Godbout (1996) examined the effectiveness of exposure and CR in a 15 session 
treatment. They measured the anxiety levels of participants at the beginning oftreatment, at the 
51h and lOth session, and at the end oftreatment. No significant differences were found between 
the two treatments, although the exposure group had consistently lower anxiety scores than the 
CR group. Overall, there was a significant reduction of anxiety levels over time, regardless of the 
treatment used; anxiety levels diminished at a steady linear rate 
An additional study investigated the process of anxiety reduction but for post traumatic 
stress disorder (Marks, Lovell, Noshirvani, Livanou & Thrasher, 1998). The researchers 
compared CR, a relaxation technique and CBT over a 10 week treatment. Anxiety was measured 
at the beginning oftreatment, at week 6 and at the end oftreatment. The pattern of anxiety 
reduction appeared to follow a linear trend. AlI the treatments groups had significantly lower 
anxiety scores compared to the relaxation group. However, there was no significant difference 
between the CR and CBT group. 
From these studies, it can be deduced that the anxiety reduction process, no matter the 
psychological treatment used, follows a straightforward linear trend with sorne indication of 
scores increasing or remaining the same towards the end oftreatment. AIso, from the process 
studies examined, neither treatment is manifestly superior to any other, as Stravynski's review of 
outcome studies concludes. 
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Exposure alone reduces anxiety quite successfully yet does not address the improvement 
of social functioning. As shown, cognitive restructuring and SST do not add any useful element 
to anxiety reduction compared to exposure. The fact that these treatments produce similar 
outcomes points to a similar therapeutic process. In addition, in terms ofimprovement in social 
functioning, SST combined with the interpersonal approach is not superior to interpersonal 
approach alone. Again, SST is not shown to be any better treatment for that aspect. 
Pharmacological treatments 
A third approach in treating SP that could provide infonnation on the anxiety reduction 
process is medication. In this section, the main medications used to treat social phobia will be 
discussed and compared for their effectiveness. 
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An overview of the outcome studies using medication was do ne by Stravynski (2007). He 
summari zed that " ... overall the various classes of medication appear to results in similar 
outcomes, with phenelzine showing a slight advantage over moclobemide [ ... ]." (Chapter 10, pp. 
305-306.). Hence, there does not seem to be a medication that is markedly superior, except that 
certain classes ofmedication have less adverse effects and are therefore preferred practically. 
Ofmore interest is the actual the pro cess ofreducing anxiety with medication. The 
existing literature for the phannacological treatment of SP is much richer in process studies. In 
one study, moclobemide took effect at week 8 of a 12 week treatment. Overall, the pattern of 
anxiety reduction was linear. However, towards the last sessions (week 8 to 12), the scores 
remained stable or increased slightly (Noyes, Moroz, Davidson, Liebowitz, Davidson & Siegel, 
1997). In another study, the trend of anxiety reduction was similar. Participants in the 
moclobemide group reported statistically significant improvements as ofweek 4 (Stein, 
Cameron, Amrein & Montgomery, 2002). 
Studies using SSRIs as treatment for social phobia report the same process of treatment. 
With fluoxamine, psychosocial impainnent, as measured by anxiety questionnaires, diminished 
linearly until week 8, afterwards the scores stabilized. Participants in fluoxamine reported lower 
anxiety throughout the whole treatment period but the difference between the placebo group was 
significant from week 5 until week 10 (Asakura, Tajima & Koyama, 2007). 
In a similar study, participants taking fluoxamine reported overall a greater reduction in 
anxiety and social phobic levels than the placebo group. For both treatment groups, the anxiety 
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reduction process was linear until week 4 in a 12 week treatment. From that point in time until 
the end oftreatment, the reduction in anxiety scores became more stable. The difference in scores 
between the medicated and placebo group became significant as ofweek 8. However, at week 1, 
scores increased for the fluoxamine group before reducing steadily until the end oftreatment 
(Stein, Fyer, Davidson, Pollack & Wiita, 1999). 
Another study of the same duration demonstrated a comparable pattern, where 
participants in the fluoxamine group reported an increase in anxiety scores between the beginning 
of treatment and week 2. From that point on, anxiety levels reduced linearly. The superior 
therapeutic gains of the medicated group versus the placebo group were statistically significant as 
ofweek 6 until the end oftreatment (week 12) (van Vliet, de Boer & Westenberg, 1994). 
The same type of medication was also used for another study, this time the fluoxamine 
group repOlied lower anxiety levels throughout the whole treatment pro cess, yet towards the end 
ofthe sessions (between week 10 and 12), the scores did not decrease as steadily. On the whole, 
the medicated group reported lower scores than the placebo but the difference became significant 
from week 4 to 12 (Davidson, Yaryuar-Tobias, DuPont, Stallings, Barbato, van der Hoop & Li, 
2004b). Another study reported that participants in the fluoxamine group displayed decreasing 
anxiety scores during the complete 12 week treatment. The differences of the anxiety levels 
between the medicated and placebo group were statistically significant only at weeks 4, 8, 10 and 
at the end oftreatment (Westerberg, Stein, Yang, Li & Barbato, 2004). 
In another study, participants in both a paroxetine and a placebo treatment group reported 
a linear reduction in anxiety levels. At mid-point, week 6, the scores for both groups levelled off 
and remained at similar levels until the last week oftreatment (week 12). Participant taking 20 
milligrams of paroxetine a day reported significantly lower avoidance and distress scores than 
participants in the placebo group from week 8 to 12. Those taking 40 and 60 milligrams of 
paroxetine a day reported significantly lower scores than the placebo group at the end of 
treatment (Liebowitz, Stein, Tancer, Carpenter, Oakes & Pitts, 2002). 
For another study comparing paroxetine and placebo, a linear reduction of anxiety was 
evident during aIl the 12 weeks oftreatment. Participants in the paroxetine group displayed 
significantly lower anxiety scores at week 6 until the end oftreatment (Lepola, Bergtholdt, 
Lambert, Davy & Ruggiero, 2004). 
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The use of sertraline for the treatment of social phobia, compared to placebo, showed that 
it was inferior to placebo in the first three weeks of a 20 week treatment but afterwards it became 
significantly superior. The pattern of anxiety reduction was linear throughout the treatment 
process but towards the end of the sessions (between week 16 and 20), the scores for both groups 
remained the same and ceased decreasing at a steady rate (van Amerigen, Lane, Walker, Bowen, 
Chokka, Goldner, Johnston, LavaIlé, Nandy, Pecknold, Hadrava & Swinson, 2001). Another 
study showed that participants in a 12 week study taking either sertraline or placebo reported a 
steady decrease in anxiety levels during the whole treatment process. The superiority of sertraline 
over placebo was significant from week 6 until the end oftreatment (Liebowitz, DeMartinis, 
Weihs, Londborg, Smith, Chung, Fayyad & Clary, 2003). 
With venlafaxine (a SNRI), the therapeutic process followed a linear trend during the first 
half of the treatment (until week 6). Afterwards, anxiety scores did not decrease as progressively 
but remained at similar levels until the end oftreatment (week 12). Participants in the medicated 
group showed significantly lower anxiety scores from week 4 to the end oftreatment (Rickels, 
Mangano & Khan, 2004). Once again for another study, the same pattern of anxiety reduction 
was observed. Also, the superior efficacy ofvelafaxine over placebo became significant at mid-
treatment (week 6 of 12) (Liebowitz, Mangano, Bradwejn & Asnis, 2005). 
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As for the other classes of medications, the comparisons between placebo and medication 
follow a somewhat different treatment process. In the use of gabapentin and placebo, during a 14 
week treatment process, the anxiety reduction pattern is not as consistent with a linear trend. The 
reduction is more graduaI and at the last sessions (between week 10 and 14), the levels increase 
slightly (Pande, Davidson, Jefferson, Janney, Katzelnick, Weisler, Greist, & Sutherland, 1999). 
For participants taking pregabalin, anxiety levels reduced at a linear pace during the first 4 weeks. 
After that, they remained more or less the same (Pande, Feltner, Jefferson, Davidson, Pollack & 
Stein, 2004). 
Wh en comparing different types ofmedication, the treatment process remains essentially 
linear. One study compared moclobemide and phenelzine and found both drugs decreased anxiety 
linearly for the whole 16 week treatment. Both drugs pro duce equivalent scores but participants 
taking phenelzine did however report more side effects than those taking moclobemide (Versiani, 
Nardi, Mudim, Alves, Liebowitz & Amrein, 1992). 
Wh en comparing moclobemide and citalopram, anxiety scores decreased linearly until 
week 4 of an 8 week study, afterwards the scored remained at similar levels for both groups. For 
the citalopram group, there was a minor increase in the scores at week 6 before decreasing 
slightly. No statistically significant differences were found in this study between the two 
medications (Atmaca, Kuloglo, Tezcan & Unal, 2002). 
In another study comparing clonazepram combined with paroxetine and paroxetine 
combined with placebo, it was found that all the treatment groups reported a continuous 
reduction in anxiety until week 6 of a 20 week study. From that point, the scores plateaued and 
remained at the same levels. The differences between the scores of the treatment groups were not 
significant (Seedat, & Stein, 2004). 
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In summary, whether comparing medication and placebo or two classes of drugs, the 
anxiety reduction process is comparable. During the first half of the treatment process, the 
reduction of anxiety follows a linear pattern, in sorne cases there is an increase in anxiety before 
the reduction takes place. Towards mid-treatment or the late sessions, the anxiety levels stabilize 
and do not fall as much. This steadying of anxiety levels, also found in the combination and 
psychological studies, invites further exploration to determine if it is a regular occurring pattern. 
Wh en comparing medication and placebo, the drug treatment appears to show its effects towards 
the middle of the treatment. At best, medication reduces anxiety levels at a fairly quick rate but 
do es not improve social functioning. 
Current Study 
As outlined in the literature review, there is a significant amount of evidence on the 
outcome of anxiety levels for SP treatment studies but very little on the process that leads to it. 
Furthermore, the CUITent class of medication used to treat SP has not been compared or combined 
to a psychological approach. To address such a disparity, the present study aims to ascertain if a 
combination of a SSRI and an interpersonal approach to therapy is more effective at reducing 
anxiety during a 12 week treatment than interpersonal therapy alone. 
Because ofits multi-pronged advantage (improved social functioning and anxiety 
management), it is expected that a combination treatment would produce lower anxiety levels 
than a single approach treatment by simultaneously reducing anxiety via medication and 
psychotherapy. As for the process of anxiety reduction, based on previous process studies (be it 
combination, psychological or pharmacological studies), they showed that no matter the 
treatment used, reductions in anxiety followed linear patterns and towards the end oftreatment a 
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steadying of anxiety levels was noticeable (Clark et al., 2003; Stravynski et al., 1987; van 
Arnerigen et al., 2001) . Moreover sorne studies, again using different types oftreatrnent, have 
actually reported increases in anxiety during treatrnent (Otto et al., 2000; Cottraux et al., 2001; 
Pande et al. 1999). However, with the interpersonal approach, the process of anxiety reduction 
would follow a slightly different pattern based in its theoretical frarnework. In Stravynski's book 
(2007), he explains that the interpersonal approach atternpts to replace the self-protective patterns 
with new strategies, prornoting participation in social encounters. This entails facing challenging 
situations during therapy that could at first increase anxiety before any irnprovernents surface. 
With those considerations in rnind, the following hypotheses are formulated for this 
study: 
Outcome Hypothesis: 
(1) The combined treatrnent condition, paroxetine and the interpersonal approach to therapy, 
will report significantly lower anxiety levels than the interpersonal approach alone at the end 
of treatrnent. 
Process Hypotheses: 
(2) The participants in the interpersonal condition will report increases of anxiety at the 
begüming oftreatrnent. 
(3) Both experirnental conditions will report linear reductions in anxiety between the 
beginning and end oftreatrnent. 
(4) The anxiety levels for both experimental conditions will stabilize towards the end of 
treatment. 
Method 
This study was part of a large-scale investigation by Stravynski et al. (2006). 
Participants 
A total of 48 social phobie participants, 30 males and 18 females, took part in the study. 
Participants were recruited through referrals of the L.H. Lafontaine Hospital in Montreal and 
advertisement on the CRFS and Social Anxiety Clinic (University of Montreal) websites. Those 
interested contacted the CRFS by telephone or email and underwent a twenty-minute telephone 
interview to ascertain that the difficulties of the potential participant are mostly of social phobie 
nature. It consisted of six questions (open and closed ended) about participants' current 
difficulties (Appendix 1). Participants were asked for their contact information, whether they 
consumed alcohol, took medications and had previous consultations for mental health issues. 
They were also asked if they had any depressive complaints, what type of social difficulties they 
were experiencing and how frequent these difficulties occurred. 
Prospective participants who seemed to be socially phobie during the telephone interview, 
were over the age of eighteen, were not taking any psychotropic medication and did not have any 
other cormobid complaints were scheduled for an in-person unstructured psychiatrie evaluation 
(lasting 90 minutes) with one ofthree psychiatrists of the L.H. Lafontaine Hospital, Drs. Sidoun, 
Fabian and Todorov, to determine ifthey met the DSM-IV criteria for social phobia. This was 
done again by a clinical psychologist foUowing a subsequent interview based on the ADIS-R. 
An inter-rater agreement regarding social phobia was established. In the case of disagreement, 
the participant was exc1uded. 
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After the psychiatric interviews, 59 participants were included in the study. 31 
participants were assigned to the interpersonal condition and 28 participants to the combined 
condition. At the end oftreatment, 48 participants remained, 24 in the interpersonal condition (11 
males and 13 females) and 24 in the combined condition (19 males and 5 females). The mean age 
of the sample was 37.55 (SD= 10.74), with an average education level of 15.02 years (SD= 3.21). 
Most participants were single (40%) or with a partner (37.5%), with limited years of cohabitation 
and few had children. The majority ofparticipants were French-speaking (96%). The average 
duration of social phobic problems were 23.81 years with onset in early adolescence. See table l 
(p. 22) for sample characteristics. 
AlI participants reported public performance, su ch as making a speech, as a difficulty 
experienced in their daily lives. The majority of the sample (approximately 69%) also feared 
blushing when spoken to. In the interpersonal group, interpersonal fears (70.8%), i.e. difficulty 
maintaining relationships at work, with friends and family members, was a main complaint 
followed by fear of sweating in a social situation (54.2%). In the combined group, 41.7% of 
participants complained ofinterpersonal difficulties and 37.5% feared public sweating (see table 
II, p. 23) 
Exclusion criteria 
Potential participants under the age of eighteen were excluded from this study. 
Participants who were allergic to paroxetine or those who had a high risk of suicide as well as 
those who were pregnant or breast-feeding were excluded. Furthermore, participants who were 
on benzodiazepines, MAOI's, or had a history of chronic abuse ofpsychotropic medication were 
not included. Finally, participants who did not meet criteria for social phobia according to the 
DSM-VI (from both the psychiatrists and clinicians) and have it as the main clinical complaint 
were excluded. A total of 14 participants were excluded because ofthese various criteria. 
Table I. Means (and standard deviations) of demographic and clinical characteristics of the 
sample. 
Age (years) 
Years of schooling 
Years of cohabitation 
Numbers of children 
Duration ofproblems 
Age ofonset 
Interpersonal 
(n=24) 
Mean (s.d.) 
37.42 (11.23) 
15.29 (2.77) 
4.84 (8.09) 
0.67 (0.92) 
22.94 (14.78) 
14.48 (13.36) 
Note: ns (not significant) 
Combined 
(n=24) 
Mean (s.d.) 
37.67 (10.24) 
14.75 (3.64) 
9.05 (12.06) 
0.63 (1.01) 
24.67 (13.19) 
13.00 (8.36) 
Statistics 
t 
-0.08ns 
0.58 ns 
-1.42 ns 
0.15 ns 
-0.43 ns 
0.51 us 
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Table II. Demographic and clinical characteristics ofthe sample. 
Characteristic 
Demographie: 
Sex 
Male 
Female 
Clinical 
Phobia Features: 
Blushing 
Shaking 
Public performance 
Dysmorphophobia 
Social dysfunction 
Panic 
Using public toilets 
Sweating 
Interpersonal 
Swallowing 
Vomiting 
Suffocating 
* p:::; .05 
Interpersonal 
(n=24) 
n % 
11 45.8% 
13 54.2% 
17 70.8% 
5 20.8% 
24 100.0% 
0 0.0% 
5 20.8% 
0 0.0% 
2 8.3% 
13 54.2% 
17 70.8% 
6 25.0% 
0 0.0% 
3 12.5% 
Combined 
(n=24) 
n % 
19 79.2% 
5 20.8% 
16 66.7% 
8 33.3% 
24 100.0% 
2 8.3% 
3 12.5% 
4 16.7% 
6 25.0% 
9 37.5% 
10 41.7% 
3 12.5% 
0 0.0% 
2 8.3% 
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Statistics 
i 
5.69* 
0.10 
0.95 
2.09 
0.60 
4.36* 
2.40 
1.34 
4.15* 
1.23 
0.22 
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Assessment 
Al! participants completed the assessment battery one week before the first session (T 0), at 
sessions 1 (Tl), 2 (T2), 6 (T3), 10 (T4), and 12 (Ts). The battery is discussed in detail in the next 
section. 
Clinical interviews 
The Anxiety Disorders Interview Schedule (ADIS-R) used by the clinical psychologists is 
a structured interview designed to identify anxiety disorders such as social phobia, agoraphobia, 
generalized anxiety disorder and post-traumatic stress disorder according to DSM-IV criteria (di 
Nardo, Moras, Barlow, Rapee, & Brown, 1993). It assesses fear in a variety of social situations 
(parties, meetings, etc.). The ADIS-R presents good inter-rater agreement of K = 0.857 for social 
phobia and other anxiety disorders (Blanchard, Gerardi, Kolb, Barlow, 1986). Bouman and de 
Ruiter (1991) found that the ADIS-R has good concurrent validity with the Diagnostic and 
Statistical Manual of Mental Disorders-III--Revised (DSM-III--R) and the Symptom Check List-
90. This means that the ADIS-R is able to detect disorders as efficiently as other existing 
instruments. The ADIS-R differentiates among various anxiety disorders, such as agoraphobia, 
generalized anxiety disorder, social phobia, and detects psycho sis, substance abuse and major 
affective disorders in addition to the principal complaint. 
Selfreports: Subjective anxiety 
The battery consisted oftwo self-report questionnaires measuring anxiety: 
1. The Social Avoidance and Distress scale (SAD) is a 28-item true-false inventory about 
avoidance and discomfort during social encounters and interpersonal relationships (see Appendix 
II) (Watson & Friend, 1969). The SAD consists oftwo subscales: (1) subjective distress, (2) 
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avoidance. Examples of items of the two subscales are: 1 feel comfortable even in unusual social 
gatherings (subjective distress) and 1 often find excuses to avoid social obligations (avoidance). 
The final score is a summation ofthe "true" responses. 
SAD Reliability. The two SAD subscales have a high correlation of 0.75. The test-retest 
reliability is .68 and internaI consistency 0.9 with a student population (Watson & Friend, 1969). 
InternaI consistency is simi1arly high, 0.94, with a clinica1 population (Oei, Kenna & Evans, 
1991). 
SAD Validity. The predictive validity of the SAD had been evaluated by Watson and 
Friend (1969). High scores on the SAD predicted greater concern and reluctance to participate in 
future group discussions. Furthermore, those who scored high tended to speak less during 
sessions. 
As for convergent validity, the SAD is correlated to the Taylor Manifest Anxiety (-0.54), 
the Audience Sensitivity Index (-0.76), the Jackson Personality Research Form (-0.76) and the 
Marlowe-Crowe Social Desirability Scale (-0.25). This suggests that the SAD corresponds 
strongly to other measures of similar constructs. The discriminant validity of the SAD has been 
studied by Oei, Kenna & Evans (1991) with phobie individuals. Social phobies scored 
significantly higher than simple phobies and panic disorder participants. In summary, the SAD 
has established psychometrie features with especially strong predictive validity. 
2. The Fear Questionnaire (FQ), is 20-item scale that measures three different phobias: 
agoraphobia, social and blood-injury (see Appendix III) (Marks & Matthews, 1979). Items 4, 5, 
7, Il and 14 measure agoraphobia, items 1,3,9, 12 and 15 measure blood injury and items 2,6, 
8, 10 and 13 measure social phobia on a scale of 0, would not avoid it, to 8, always avoid it. An 
example of an item for social phobia would be: Speaking or acting to an audience. Items 16 to 20 
measure emotional distress on a scale of 0, at all disturbing, to 8, very severely disturbing. An 
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example of items in this category is: Feeling you or your surroundings are strange or unreal. For 
the purpose of this study, only questions pertaining to social phobia and emotional distress were 
used fr0111 the FQ. The advantage of the FQ is that it is quick to complete, easy to score and it 
emphasizes agoraphobic and social phobic items. The total score is derived by summing the scale 
number chosen of each item. 
FQ Reliability. The test-retest reliability is between 0.81 and 0.96 (Marks & Matthews). 
The FQ has been shown to have adequate internaI consistency with a correlation of 0.45 (Lee & 
Oei, 1994). 
FQ Validity. For discriminant validity, the FQ correctly differentiates between the 
different phobias it measures, especially for the social phobia subscale in relation to anxiety 
(Cox, Swinson & Shaw, 1991; van Zuuren, 1988; Mavissakalian, 1986). Its validity has been 
verified among normal and clinical populations. (Osman, Barrios, Osman & Markway, 1993; 
Moylan & Oei, 1992). As for convergent validity, the FQ demonstrates moderate correlations 
with the State Anxiety Inventory (0.25), the Trait Anxiety Inventory,(0.27), the Modified 
Catastrophic Cognition Questionnaire (0.32) and the Anxiety Sensitivity Index (0.44) (Lee & 
Oei). Furthern10re, the questionnaire has been applied to various cross-cultural populations with 
similar results (Moylan & Oei). Overall, the FQ possesses adequate reliability and validity for use 
on various populations. 
Treatment 
After being assigned to either the interpersonal or combined group, participants met with 
one oftlu'ee psychologists, Drs. Arbel, Roy and Amado to confirm social phobia with the ADIS-
R, as well as gather information on their psychosocial functioning. A 'functional analysis' 
interview was conducted to determine each participant's social phobic problems as occurring in a 
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social setting. Commons problems identified were performance duringjob interviews, work-
related interactions and social gatherings.Goals and targeted behaviours were set with the 
therapist to counter specific problems and improve participation. During that meeting (T 0), 
participants read and signed consent forms (see Appendix IV) agreeing to participate in the study 
and completed the SAD and FQ questionnaires. The meeting lasted approximately three hours. 
The interpersonal approach 
Participants both in the psychotherapy and combined group attended twelve weekly 
sessions of the interpersonal approach to therapy lasting two hours each. The sessions were 
conducted in groups of six participants with a senior therapist and a co-therapist. The therapists 
were clinical psychologists with over ten years of experience in the treatment of social phobia. 
The interpersonal approach is described in Stravynski (2007, pp. 299-300). The sessions 
involved training to develop new non-defensive interpersonal ways of dealing with real-life 
social situations. The goal of developing the se new ways ofbehaving is to enable the individual 
to actively participate in their various social activities. Because participants are expected to face 
challenging social situations both during sessions and in real-life situations, anxiety levels would 
possibly increase at first. After repeatedly acting out the new interpersonal ways ofbehaving, 
anxiety levels along with the defensive pattern would subside. 
Although this treatment was conducted in a group, each participant had individualized 
treatment goals tailored to their particular circumstances. The group context ofthis therapy 
provides an adequate setting to enact target behaviours of social nature. 
The sessions involved training to improve targeted individualized participatory 
behaviours and actions. During the sessions, participants received instructions and guidelines by 
the therapist to enact their chosen targeted behaviour. The therapist or another participant 
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modeled the particular desired behaviour or interpersonal individualized treatment target through 
role-rehearsal. The participant th en rehearsed his targeted behaviour with the therapist or another 
participant. At the end of the enactment, feedback was given on their role-rehearsal in the forrn of 
suggestions from the therapist and the other participants of the group on how to improve the 
enactment. At the end of each session, homework was given to each participant to practice the 
target behaviour in real-life situations. Furtherrnore, they were asked to monitor the frequency of 
each target's perfom1ance and note their level of anxiety experienced during its enactment. The 
homework was reviewed at the beginning of the next session. Each participant received 20 
minutes of therapeutic attention every session to model and rehearse their target behaviours and 
observed or participated indirectly during other participants' modeling and rehearsals. 
The following is an example of a session ofthe interpersonal approach to therapy dealing 
with a difficulty speaking during a work related meeting. The targeted behaviour would be to 
express an opinion. The therapist would ask aIl the participants to re-enact such a situation within 
the session. Afterwards, the therapist wou Id suggest and model techniques to help the specific 
participant to take part actively in meetings. The participant would put the trained behaviour in 
practice between sessions and as part oftheir homework; they would apply these techniques 
during actual meetings and note their feelings of anxiety and impressions in ajournaI. In the next 
session, they would review their homework notes with the therapist and discuss their progress. 
Combined group 
In addition to the interpersonal approach treatment, participants in the combined group 
were prescribed paroxetine (an SSRI). This aspect oftreatment was administered by one oftwo 
psychiatrists, Drs. Sidoun and Todorov from the L.H. Lafontaine Hospital. A table outlining the 
protocol for administering paroxetine was used for this study (see Appendix V). The participants 
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who received the combined therapy started with a 10 or 20 m.g./day ofparoxetine, with a treating 
physician following the protocol table. The maximum dose was 50 m.g./day. If a participant 
experienced an adverse reaction, a 10 m.g./day reduction was applied. Those that required more 
than one dose readjustment were excluded from the study. The participants met with one of the 
two psychiatrists five times during the twelve week sessions to receive a paroxetine prescription 
and adjust the dosage. The pharmacotherapy supervisions lasted approximately twenty minutes. 
Weekly individual supervision and clinical team meetings were he Id to ensure the treatment 
protocol was being administered appropriately and to address any issues or problems. 
Dosage 
The dosages prescribed to each participant in the combined group during the five 
supervision sessions were noted and analyzed. The descriptive statistics of the dosage levels of 
the participants ofthe combined group can be seen in table III (p.30). At session 1, the mean 
dosage was 12.50 (SD= 4.4). For session 2,3,4 and 5, the mean dosages (with standard 
deviations in parentheses) were 22.29 (SD= 7.2), 27.50 (SD= 12.6),28.33 (SD= 13.1) and 10.83 
(SD= 6.5) respectively. The highest mean dosage level was during the fourth supervision (see 
figure 1, p. 31). Thus, the dosage protocol was closely followed, as displayed by the data. 
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Table III. Paroxetine dosagea in the combined condition. 
Time 
Mean (s.d.) Median Mode Minimum Maximum Variance Range 
Session 1 12.50 (4.4) 10.0 10.0 10.0 20.0 19.57 10.0 
Session 2 22.29 (7.2) 20.0 20.0 5.0 40.0 52.13 35.0 
Session 3 27.50 (12.6) 25.0 20.0 5.0 50.0 158.70 45.0 
Session 4 28.33 (13.1) 30.0 30.0 5.0 50.0 173.19 45.0 
Session 5 10.83 (6.5) 7.5 10.0 5.0 30.0 42.75 25.0 
a Note: in mg. 
31 
30 
25 
20 
VJ 
S 
ro 
~ 15 
~ 
10 
5 
0 
Session 1 Session 2 Session 3 Session 4 Session 5 
Time 
Figure 1. Mean dosage of patients in the combined group across time. 
Results 
Participation rates 
789 individuals seeking treatment for social phobia contacted the CRFS and underwent a 
screening telephone interview. Ofthat number, 89 were not eligible (11.3%) following the 
telephone interview, 531 declined to participate because ofwaiting list delays (67.3%), and 169 
were eligible and accepted to be evaluated (21.4%). Those scheduled for a psychiatrie evaluation, 
44 did not present themselves (26%), even after several re-schedulings, and 10 were excluded 
because they met exclusion criteria, e.g. such as depression and/or self-medication with alcohol 
or other substances. 
115 individuals ;were asked to come in for the pre-treatment appointments. 27 participants 
did not attend the appointment and 4 individuals were excluded over disagreement regarding the 
diagnosis between the clinicians and psychiatrists. Thus, 84 participants were on a waiting list for 
the treatment to begin. 21 dropped out during the waiting period. Of 63 individuals who were 
contacted to begin treatment, 4 declined because they had found alternative treatment. 
In total, 59 individuals began treatment; 30 were randomly assigned to the interpersonal 
condition and 29 to the combined condition. During treatment, 6 participants from the 
interpersonal condition dropped out and 4 participants from the combined condition dropped out. 
At post-treatment, 1 participant from the interpersonal condition dropped out. (see Figure 2, p. 
33, for participant flowchart). 
Figure 2. Flowchart of the study 
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I....---.;.;..;.;.;;,.......;~-....J 
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......... Found alternative CD 
treatment 
G) Oropout ........ I....-....;.;;......,r-----' 
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Descriptive statistics 
The mean scores and standard deviations for each treatment group on every self-report 
questionnaire and its subscales were derived for each measure in time: beginning oftreatment 
(To), session 1 (Tl), 2 (T2), 6 (T3), 10 (T4) and 12 (Ts). These descriptive statistics are presented 
in tables IV-VI (p. 35) for the SAD Total scores and its subscales, and in tables VII-IX (p. 36) for 
the FQ Composite scores (the combined subscales scores) and its subscales. 
F correction 
Before proceeding to testing the hypotheses, certain assumptions needed to be tested to 
ensure homogeneity of the data. To ascertain that the effects of the two experimental conditions 
were consistent, Mauchly' s Test of Sphericity was conducted. This test determines whether the 
assumption of sphericity was violated and hence the F statistic of each effect needs to be 
corrected. 
As the SAD Total score,;( (14, N= 48) 29.48, p :::;;.01, and the Avoidance subscale,;( 
(14, N= 48) = 43.23, P :::;;.001, produced chi-squares with an associated alpha level of 0.5 or less, 
the assumption of sphericity was violated. The Huynh-Feldt epsilon value was used to adjust the 
degrees of freedom and the corrected F values were used. For the SAD Distress subscale, the FQ 
Composite score and its subscales, the assumption of sphericity was not violated, therefore no 
correction was required. 
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Table IV. Means (and standard deviations) of the SAD Total. 
Interpersonal Combined 
Time 
Mean (s.d.) Mean (s.d.) 
Before treatment 20.6 (4.8) 22.8 (5.6) 
Session 1 15.2 (11.5) 25.3 (3.5) 
Session 2 13.1 (7.8) 17.0 (4.9) 
Session 6 10.7 (6.2) 11.3 (4.5) 
Session 10 10.1 (7.2) 10.5 (7.5) 
Session 12 9.2 (7.1) 7.7 (6.9) 
Table V. Means (and standard deviations) of the SAD Avoidance subscale. 
Interpersonal Combined 
Time 
Mean (s.d.) Mean (s.d.) 
Before treatment 8.5 (3.4) 10.4 (2.9) 
Session 1 5.0 (4.6) 9.8 (2.8) 
Session 2 5.8 (3.4) 7.5 (2.2) 
Session 6 6.3 (3.9) 6.5 (2.7) 
Session 10 3.1 (2.8) 4.8 (3.6) 
Session 12 2.8 (2.2) 3.2 (2.7) 
Table VI. Means (and standard deviations) of the SAD Distress subscale. 
Interpersonal Combined 
Time 
Mean (s.d.) Mean (s.d.) 
Before treatment 12.2 (2.4) 12.4 (3.0) 
Session 1 7.5 (5.6) 12.3 (2.8) 
Session 2 7.8 (5.0) 10.1 (3.0) 
Session 6 5.1 (2.9) 5.4 (2.3) 
Session 10 7.6 (5.4) 6.2 (4.6) 
Session 12 7.0 (5.8) 5.0 (4.9) 
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Table VII. Means (and standard deviations) of the FQ Composite. 
Interpersonal Combined 
Time 
Mean (s.d.) Mean (s.d.) 
treatment 46.3 (9.7) 43.1 
Session 1 42.3 (10.8) 36.8 (13.1) 
Session 2 39.8 (10.6) 35.2 (14.0) 
Session 6 35.5 (12.0) 27.8 (14.3) 
Session 10 32.3 (8.9) 22.4 (12.2) 
Session 12 32.3 (8.9) 22.4 (12.2) 
Table VIII. Means (and standard deviations) of the FQ Social Phobia subscale. 
Interpersonal Combined 
Time 
Mean (s.d.) Mean (s.d.) 
Before treatment 23.1 (7.3) 24.1 (6.7) 
Session 1 20.8 (9.1) 22.0 (6.3) 
Session 2 20.4 (8.0) 21.9 (7.2) 
Session 6 17.7 (7.6) 16.7 (8.4) 
Session 10 16.9 (6.9) 14.2 (7.3) 
Session 12 16.9 (6.9) 14.2 (7.3) 
Table IX. Means (and standard deviations) of the FQ Emotional Distress subscale. 
Interpersonal Combined 
Time 
Mean (s.d.) Mean (s.d.) 
Before treatment 22.1 (5.9) 19.4 (8.0) 
Session 1 20.9 (6.4) 15.3 (8.0) 
Session 2 18.4 (8.0) 13.7 (8.2) 
Session 6 17.5 (8.6) 11.6 (7.9) 
Session 10 15.0 (6.0) 8.8 (7.5) 
Session 12 15.0 (6.0) 8.8 (7.5) 
37 
Test of Equality of Variance-Covariance 
A second test ofnonnality of the data was Box's Test of Equality of Covariance. This test 
1S used to detennine whether the variance ofthe SAD and FQ scores were equal between the 
interpersonal and combined conditions. 
The SAD Total scores and the Avoidance subscale yielded statistically significant values, 
F (21, 7782.65) = 3.58 and F (21, 7782.65) = 2.45,p '5.001. The Distress subscale also displayed 
significantF(21, 7782.65) 3.12,p '5.001. Thismeansthattheobserved variance-covariance of 
the SAD questionnaire and its subscales are not equal between the conditions. However, since the 
sample sizes of the two conditions are equal, the effect ofviolating this assumption was minimal. 
As for the FQ Composite score and its subscales, the assumption ofnonnality was not violated. 
Inferential statistics 
To test the hypotheses ofwhether the combined group is a more effective treatment in 
reducing anxiety, repeated measures analysis ofvariance (ANOVA) was conducted (see table X, 
p. 38). The design was a 2X6 with six points oftime, To to Ts , and two levels oftreatment, 
interpersonal and combined conditions. 
Change in anxiety across lime and treatment group. Significant improvements in time for 
participants in both experimental conditions were found for the SAD Total score, F (4.37, 
201.00) 7.06,p S.OOI, the SAD Avoidance subscale, F (4.02, 185.12) = 5.02,p S.OOI, the 
SAD Distress subscale, F (5,230) 7.44,p S.OOI, the FQ Composite score, F (5, 160) = 2.34,p 
S.05., and the FQ Social Phobia subscale, F (5, 170) = 2.34, P < 05. 
For the SAD Total scale, participants in the interpersonal condition displayed significantly 
lower scores than participants in the combined group from the beginning oftreatment until 
session 10. This resuIt is contrary to the second hypothesis, where the interpersonal condition was 
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Tab1e X. Change in anxiety and di stress across time and treatment group. 
Statistics 
F 
Group Time GXT 
SAD: Total 3.72 51.44*** 7.06*** 
SAD: A voidance 8.00** 40.00*** 5.02*** 
SAD: Distress 0.68 33.05*** 7.44*** 
FQ: Composite 0.05 29.63*** 2.34* 
FQ: Social Phobia 0.50 29.63*** 2.34* 
FQ: Emotional Distress 6.54* 16.60*** 0.62 
* P =::;.05; ** P ~.01; *** P =::;.001 
expected to report an increase in anxiety at the beginning of the sessions. However, in 
concordance with the first hypothesis, participants in the combined group reported lower scores 
by session 12. 
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Participants in the interpersonal condition had significantly lower SAD Avoidance scores 
at the beginning oftreatment and at sessions 1,2, 10 and 12. At session 6, participants in both 
experimental conditions reported equivalent scores. These results did not support the proposed 
hypothesis of the combined treatment being more effective and reducing avoidance behaviours 
and distress at end oftreatment. Moreover, no increases in anxiety scores were detected at the 
beginning of the sessions for the interpersonal condition, as expected by the second hypothesis. 
For the SAD Distress subscale, participants in the interpersonal condition had 
significantly lower scores at the beginning oftreatment and at sessions 1 and 2. Once again, the 
second hypothesis is not supported with these results. At session 6, participants in both 
experimental conditions reported equivalent scores. At sessions 10 and 12, participants in the 
combined group yielded significantly lower scores than the interpersonal condition. These results 
support the first hypothesis. 
As for the FQ Composite, participants in the combined group reported lower scores than 
participants in the interpersonal condition from the beginning oftreatment until the end. These 
results partly support the hypothesis, it was expected that the combined treatment would be 
superior after a certain time delay. However, in this measure it is clearly the combined group that 
is reporting lower anxiety scores aU throughout treatment. For the Social Phobia mean scores, 
from the beginning oftreatment to session 6, the participants in the interpersonal condition 
reported lower scores. This result do es not support the second hypothesis. However, as expected, 
from session 6 until the end oftreatment, the combined group reported lower scores. 
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It seems that the interpersonal condition has greater success at reducing anxiety, both as 
avoidance behaviours and subjective distress, at the beginning oftreatment. Nonetheless, this 
effect becomes attenuated toward the middle of the treatment process when the combined group 
displays equivalent rates ofimprovement. At the end ofthe treatment, the combined group is 
more successful at further reducing avoidance behaviours and distress of the sample than the 
interpersonal condition. 
Contrary to expectations, there were no significant improvements in time for participants 
in either treatment group on the FQ Emotional Distress subscale. 
Improvement in rime. Significant improvements in time, from beginning oftreatment to 
end oftreatment, were evident for all measures and their subscales at ap value of ~.001. As 
expected, participants reported significant reduction ofFQ and SAD scores throughout the 
treatment sessions. Thus, the experience of anxiety, both as subjective distress and as the 
tendency to avoid social situations, became significantly lower from beginning to end of 
treatment. 
Treatments. Significant differences between the interpersonal and combined condition 
were found in the reported scores ofthe SAD Avoidance subscale, F (1,46) = 8.00,p ~.Ol, and 
the FQ Emotional Distress subscale, F (1, 32) = 6.54, p ~.05. Contrary to the first hypothesis, 
participants in the interpersonal condition had significantly lower scores on the SAD A voidance 
than the combined group throughout the treatment, let alone at post-treatment. 
As for the FQ Emotional Distress measure, the first hypothesis was confirmed. 
Participants in the combined group reported significantly lower scores on the FQ Emotional 
Distress subscale than the interpersonal condition, again throughout treatment as weIl at the end 
of the session. The combined treatment was thus more successful at reducing emotional di stress 
than the interpersonal condition. However, the process ofreducing anxiety of the two treatments 
did not follow the proposed hypothesis; the combined group was actually superior from the 
beginning of the treatment until the end. The insignificant F results for the SAD total score, SAD 
Distress subscale and the FQ Composite score and Social Phobia subscale mean that the anxiety 
reduction process was the same between the interpersonal and combined condition for these 
measures. These results did not support the hypothesis. 
Subsequent analyses 
EjJect size measure 
Sorne of the results of the previous analyses were ambiguous, especially between the two 
experimental conditions, and thus warrant further investigation. Because the significant 
differences in anxiety levels between the two experimental conditions were quite small and 
negligible, calculating the effect size will de termine if these differences were large enough to be 
able to use as support for the hypotheses. To identify to size ofthese observed effects, the partial 
eta squared ratio, 11/, was used. The partial eta squared value discloses the proportion of variance 
in the self-report scores. According to Cohen (1988), a large effect is 0.14 or above, a medium 
effect is between 0.4 and 0.14 and a small effect is less than 0.01. If the proportion of variance is 
large enough between the scores, then it further supports the significance of the findings. If the 
proportion of variance is found to be small, the differences between the scores, although 
significant, would be too small to support the hypothesis. 
Change in anxiety across time and treatment group. The mean difference between the 
two experimental conditions on part of the SAD measures and the FQ Composite and Social 
Phobia scores was found to be statistically significant throughout the sessions. To find out the 
size of these differences, 11p 2 was calculated. For the SAD total scores, the effect size was 11p 2= 
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0.13. This means that the size of the difference on the SAD total scores between the experimental 
conditions is moderate. The subscale of A voidance and Distress on the SAD also had a medium 
effect sizes for interaction, 11/ = 0.10 and 11/ = 0.14 respectively. For the FQ Composite and 
Social Phobia scores, the effect size were 11p2 = 0.74 and 11p2 = 0.06. Overall, the size of the 
difference on the anxiety measures between the two experimental conditions over the therapy 
sessions is modest, except for the FQ Composite which had a large effect. Although it is not as 
large as expected, the difference in effect size between the two treatments is enough to support 
the proposed hypotheses. 
Improvement in Time. In line with the hypothesis, aH the measures of anxiety were 
significantly reduced from beginning to the end oftreatment. The effect sizes for these significant 
findings were as follows: 11p 2 = 0.53 for the SAD total scores, 11p 2 0.47 for the A voidance 
subscale,1]2 0.42 for the Distress subscale, 11/ = 0.50 for the FQ Composite score, 11/ = 1.00 for 
the Social Phobia and 11p2 = 0.61 for the Emotional Distress subscale. The large effect sizes for 
the factor oftime add support to the confirmed hypothesis of substantial reduction in anxiety 
levels throughout the treatment process. 
Treatment Conditions. A significant difference was found between the interpersonal and 
the combined conditions on the SAD A voidance and FQ Emotional Distress scores only. The 
A voidanee subscale had a medium effeet size, 11p 2 0.15 as weIl as the FQ Emotional Distress 
subscale, 11/ 0.17. These effects sizes, although not as large as the previous ones, are moderate 
nonetheless and eonfirm the magnitude of the significant findings. 
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Pairwise comparisons 
Repeated measures analysis showed that there was significant improvement in time on the 
measures of aU the self-report questionnaires. However, a more refined analysis may detect at 
which point in time during t he treatment (Toto T 5) the differences became significant. Therefore, 
post-hoc pairwise comparisons (Bonferroni) were conducted for each questionnaire and subscale 
(see Appendix VI for values). 
SAD. For the SAD total scores, significant reductions in the reported scores were most 
apparent between the first half ofthe treatment sessions and the rest ofthe sessions. No 
significant reductions were noted between session 6 and the last half of the sessions. Similar 
results were also found with the SAD Distress scores, except that no significant reductions in the 
mean scores were found between sessions 1 and 2. However, with the SAD Avoidance scores, 
significant reductions were found between sessions but not between sessions 1 and 2, and 1 and 
6 and between sessions 10 and 12. 
FQ. Similarly for the FQ Composite scores and its subscales, significant reductions in the 
mean scores were detected between the early sessions and later sessions. The FQ Composite 
mean scores were significantly different between the beginning of treatment and sessions 2, 6, 10 
and 12. Significant reductions in mean scores were also evident between session 1 and 6, 10 and 
12. The mean scores for session 2 were significantly different from sessions 6, 10 and 12. 
Similar results were also obtained for the FQ Social Phobia and Emotional Distress subscales. 
These results indicate that the biggest therapeutic changes (diminishing anxiety scores) 
were between the early sessions and the late sessions. During mid-treatment (sessions 2 and 6) 
there is Ilot much significant change in the reported scores, therefore the process of anxiety 
reduction is quite graduaI during that stage. At first, anxiety scores are quite high and as the 
sessions continue, there is a slight reduction of anxiety. By the end of treatment, the scores are 
quite low wh en compared to the early stages of the treatment, which explain the significant 
findings. 
Trend analysis 
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The previous analyses demonstrated that there were significant lessening of anxiety over 
time on aU the measures and significant and considerable interaction effects on certain measures. 
To detect the pattern ofthese effects and whether they correspond to the hypothesis, trend 
analyses were performed for each significant finding. 
Linear trends. A linear trend is a pattern of the data that is consistently decreasing or 
increasing. Significant linear patterns were detected for improvements in time for all the 
measures of anxiety. In concordance with the hypothesis, all anxiety measures diminished in a 
linear fashion as the sessions progressed. For the interaction effect, significant linear trends were 
detected for the SAD total score and its subscales and the FQ Composite and the FQ Social 
Phobia subscale. Rence, on these measures, both conditions reported diminishing scores during 
the treatment sessions (see tables XVII-XIX in Appendix VII). To better illustrate a basic linear 
trend, a sample graph is displayed in Appendix VIII. 
Quadratic trends. A quadratic trend is a pattern of data that remains at constant levels (see 
Appendix VII for a sample quadratic trend graph). Significant quadratic trends for improvements 
in time were found for the SAD total scores, F (1, 46) = 4.98, p :::;;.05, and for the Distress 
subscale only, F (1,46) = l7.l7,p :::;;.001. Significant quadratic trends for the interaction effect 
were found for the SAD Distress subscale only, F (1,46) = 7.25,p :::;;.01. Since a quadratic effect 
was found, this means that the declining SAD Total and Distress scores did not continue to 
decrease at the end of the treatment process but more or less remained the same. 
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Cubic trends. A cubic trend describes a series of data that increases and decreases 
alternately. A sample cubic trend graph can be seen in Appendix VIII. Significant cubic trends 
were noted for the interaction effect for the SAD total scores, F (1,46) = 9.78,p ::;.01, for the 
Avoidance subscale, F (1, 46) = 6.52, p ::;.01, and for the Distress subscale, F (1, 46) = 12.85, p 
::;.001. As for the FQ, significant cubic trends were found for the factor oftime for the FQ 
Composite, F (1, 32) = 4.96, p ::;.05, and the FQ Social Phobia subscale, F (1, 34) = 4.96, p ::; 
.05. A significant cubic trend indicates an increase of the scores (see figures 3-8, pp.46-51). 
Specifically, on the SAD Total measure, only the combined condition reported an increase at 
session 1. On the SAD A voidance measure, at session 6, there is an increase in anxiety for the 
interpersonal condition that matched the combined condition's mean scores. As for the SAD 
Distress measure, scores increased at session 2 and 10 for the interpersonal condition. For the FQ 
Composite mean scores, the combined condition reported an increase at session 2. Both 
conditions reported an equivalent increase ofFQ Social Phobia scores at session 2. 
In sum, these results point to a general trend of the anxiety reductiori process in SP. As 
hypothesized, linear trends were found on most measures, meaning that anxiety reduces at a 
graduaI pace. Moreover, as demonstrated by the cubic trend analysis, there were increases in 
scores on sorne of the measures towards the beginning of the sessions and during mid-treatment. 
These results partly confirm the third hypotheses; there indeed were increases in anxiety levels 
but sorne ofthese occurred during the middle oftreatment, which was not expected. Therefore, 
although there were broadly linear reductions in anxiety, certain points during the sessions the 
levels increased before the therapeutic changes entered into effect. Another interesting pattern 
that was revealed by the quadratic trend analysis was a stabilizing of sorne measures at the end of 
treatment. This result confirms the hypothesis and the findings in previous studies. On the who1e, 
these analyses offer a general image of the anxiety treatment process. While from the beginning 
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Figure 3. Mean scores ofthe SAD Total scale by treatment group across time. 
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Figure 4. Mean scores of the SAD Avoidance subsca1e by treatment group across time. 
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Figure 5. Mean scores of the SAD Distress subscale by treatment group across time. 
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Figure 8. Mean scores of the FQ Emotional Distress subscale by treatment group 
across time, 
to mid-treatment there can be increases of anxiety because of the nature of the therapy (facing 
chaIIenging social situations), afterwards there is a steady decrease in anxiety. Towards the end 
of treatment, the decrease in anxiety slows down somewhat. 
Discussion 
Conclusions 
The main purpose of the study was to find out if the process of anxiety reduction of the 
combined approach would differ from a purely psychological one. Before launching into a 
discussion of this core question, 1 will briefly outline the outcome results of the two treatments. 
As expected in the outcome hypothesis, the combined treatment was more effective at 
reducing anxiety at the end of treatment than the interpersonal approach alone. This study 
counters Stravynski's conclusions that psycho-pharmacological and purely psychological 
treatments produce equivalent outcome results. Why this disparity? One possible explanation is 
in the actual types oftreatments examined. In Stravynski's review, he evaluated CR and exposure 
treatments compared or contrasted to various medications; the interpersonal approach to therapy 
was not tackled. However, this study used a less commonly used SP treatment and thus produced 
sorne interesting and different results, namely that a combined treatment for SP is superior to a 
purely psychological one. 
However, the primary purpose ofthis study was to clarify the process of anxiety reduction 
during treatment using two different approaches. The results in this study showed that anxiety 
levels during the treatment process for social phobia can be effectively lowered with both 
approaches. As expected in the third hypothesis and confirmed with the linear trend analysis, 
anxiety was found to decrease in an overaIl linear fashion on almost aIl of the measures for both 
the single and combined treatrnent. There exists a significant amount of evidence in the reviewed 
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literature of a linear reduction in anxiety during treatment using a variety of approaches (Clark et 
al., 2003; van Amerigen et al., 2001, etc.). In the study ofStravynski et al. (1987, p. 28), 
subjective anxiety " ... was found to decrease in a linear fashion." This study further substantiates 
that process. 
Even though participants experienced anxiety for a significant part oftheir lives (average 
duration 24 years, average age 38 years), the majority ofthem improved with this treatment. 
During the treatment process, participants had to actively engage in role play in sessions, either 
being the 'centre of attention' by doing a mock presentation or posing as a spectator. 
Participatory social behaviours leamed during the sessions also had to be applied in reallife 
situations. These requirements would be enough to cause significant levels of anxiety for the 
social phobic. Thus, rather than a reduction of anxiety at the beginning of treatment, an increase 
in anxiety would likely occur. 
As such, the second hypothesis was that participants in the interpersonal condition alone 
would experience an increase in anxiety during the first few sessions because of the nature of the 
therapy. The addition ofmedication with therapy would not increase or reduce such a spike in 
anxiety levels because there would be a certain time period before the anxiety reducing properties 
of the drug would take effect. Contrary to expectations, there were no increases in anxiety for the 
interpersonal condition at the beginning of the sessions. Rather, it was the combined condition 
that reported increases at the beginning. However, with the interpersonal approach treatment, 
there are many more increases in anxiety levels during mid-treatment or further along. 
Why are these results at odds with the hypothesis? Again, it could be due to the nature of 
the therapy. The interpersonal approach to therapy requires the participant to face distressing 
social situations and in addition, actively participate in them. Therefore, it was proposed that, at 
first, participants wou Id be quite anxious before becoming more accustomed to the process. 
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Increases of anxiety levels at the beginning of the sessions would be expected and then a steady 
decrease would enter into effect. Yet, no increases at the beginning were noted, it was towards 
mid-treatment that the interpersonal condition reported increases in anxiety scores. The nature of 
the therapy, with the repeated exposure to anxiety-filled scenarios and without the help of 
medication to manage this anxiety, would explain such a pattern. This issue will be discussed 
more in detail in the next section. As for the combined condition, why was there an increase at 
the beginning ofthe sessions? This could be because the medication did not take effect right 
away, and thus anxiety levels increased slightly before the effects of paroxetine manifested. 
On the whole, the combined group reported fewer increases in anxiety scores and the 
increase that was reported was at the very beginning of the treatment process only. The anxiety 
reduction process was more linear and steadier for the combined group. Therefore, the addition of 
medication with the interpersonal approach to therapy manages anxiety more effectively (fewer 
increases in anxiety scores) during treatment than the interpersonal approach alone. 
Despite such an increase in anxiety at certain points of the treatment process, dropout 
rates were equivalent with past studies using similar treatments. In previous studies using the 
interpersonal approach to therapy (Stravynski et al., 2000), dropout rates were between 20-25%. 
In the CUITent study, the interpersonal condition had about a 23% dropout rate. Although the 
interpersonal approach to therapy has an added advantage improving social functioning in as weIl 
as reducing anxiety, still shows sorne deficiencies in its treatment process as evidenced by the 
dropout rates. In the combined group, the dropout rate was 14%. As a result, the addition of 
medication to the interpersonal approach to therapy helps manages anxiety more effectively and 
thus fewer participants drop out. This result further bolsters the anxiety reduction effectiveness 
of the combined treatment. 
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Thus far, the general anxiety reduction process for SP, whatever the treatment approach, 
followed a confinned linear pattern. These results in this study mirror previous studies in that 
whichever treatment approach used, there is a linear reduction in anxiety during the treatment 
process. Neveliheless, there were sorne increases in anxiety levels during certain point in time of 
the therapy. 
The fourth process hypothesis, based on past process studies, was that anxiety scores for 
both experimental conditions would taper off at the last sessions. Indeed, quadratic trends were 
found on the SAD Distress measure for both experimental conditions. Hence, the reported scores 
stabilized for both groups between session 10 and 12. This confinns the pattern found on several 
past studies, again using different treatments but arriving at similar patterns at the end of 
treatment (e.g.: Davidson et al. 2004a; Prasko et al. 2006; Stravynski et al. 1987; Stein et al. 
2002; Asakura et al. 2007). 
To summarize the process of anxiety reduction found in this study, there was a strong 
linear trend for both experimental conditions, as found in the process studies reviewed. AIso, the 
same studies found sorne increases in anxiety at the beginning of treatm ent. In this study, that 
pattern was found for the combined group but the interpersonal condition had greater number of 
increases at various points ofthe treatment. It is this specific pattern that differentiates the two 
treatment approaches. Finally, the reviewed process studies noted a stabilizing of anxiety levels 
towards the end oftreatment, no matter the type oftreatment. This trend was found in this study 
as well, for both experimental conditions. 
In the end, is the anxiety management process of a combined approach superior to a 
purely interpersonal approach? Based on trend analyses, effect sizes and dropout rates, the 
combined treatment is more effective at reducing anxiety during treatment and at post-treatment. 
Both treatment approaches showed a linear reduction in anxiety during treatment and a stabilizing 
effect towards the last sessions but the combined condition reported fewer increases in anxiety 
during treatment. 
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As a non-medication alternative, the interpersonal approach to therapy is an effective 
treatment on its own. Not only does interpersonal approach to therapy target the defensive self-
protective patterns of the social phobic and improves social functioning, it adequately reduces the 
experience of anxiety. However, this treatment still shows sorne deficiencies in its anxiety 
management process; seven participants stopped treatment in this study. Clinicians would benefit 
from such knowledge when deciding on which treatment approach to use. 
AlI told, the anxiety reduction process of the combined approach is a more stable 
treatment, thus fewer participants discontinue their treatment (four dropouts versus seven from 
the interpersonal condition) allowing the therapeutic gains (i.e.: improved social functioning) to 
be realized. 
Theoretical Conclusions 
For a purely psychological treatment ofSP, the interpersonal approach to therapy takes 
effect early on in the treatment in terms of reducing anxiety but is not as stable as a combined 
treatment approach. During certain sessions, several increases in anxiety levels were noted with 
this treatment, indicating an unstable reduction in anxiety. This pro cess could explain the dropout 
rates of past studies and the CUITent one. Interpersonal approach to therapy requires participants to 
face fearful social situations, thus actually increasing anxiety before any therapeutic benefits 
manifest. Yet there were more increases and during later stages in the treatment than expected. 
Therefore, the process of anxiety reduction for the interpersonal approach is more complex than 
previously thought. 
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Participants engaging in an interpersonal approach to therapy do not only experience 
temporary increases in anxiety at the beginning but throughout the whole process. The 
explanation of this effect can lie in not only the nature or this psychological treatment but also in 
the duration. Over the course of the 12 sessions, each participant had more than one target 
behaviour to practice. At the beginning of treatment, facing and enacting the first target 
behaviour can cause an increase in anxiety but after practicing a few times the individual 
becomes more comfortable and the anxiety decreases. However, when the next target behaviour 
is introduced during the following sessions, the individual once again experiences an increase of 
anxiety before the role playing and exposure reduce the levels once more and so on. 
The spikes in anxiety levels during the therapy sessions are inevitable and necessary 
because the individu al must learn to face and experience the distressing state of anxiety in order 
to break the cycle of avoidant and defensive patterns. But are these increases in anxiety so 
overwhelming for sorne that they decide to drop out oftreatment completely? It appears so, but 
fortunately only a small number ofindividuals did withdraw from this study. Nevertheless, 
improving this treatment to ensure that aIl participants are able to complete it would be beneficial 
to not only the social phobic (gaining therapeutic improvements or even achieving remission by 
completing the sessions) but also to the clinicians (few drop outs, therefore better management of 
resources and time). 
Based on the results of this study, the combined approach does manage anxiety more 
effectively during treatment than the interpersonal approach. A combined psycho-
phannacological approach has the double advantage ofimproving social functioning through the 
interpersonal approach to therapy while blocking the physical arousal associated with anxiety by 
means ofmedication. The latter part of the combined treatment allows the individuals to learn 
new non-defensive ways of dealing with social situations without being incapacitated with 
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overwhelming physical complaints (sweating, palpitations, muscle tremors). Although there was 
an increase in anxiety at the beginning of the sessions only, the anxiety reduction process of the 
combined treatment followed a much more stable decrease in anxiety. It seems that a combined 
approach stabilizes the increases in anxiety to allow the therapeutic gains ofthe interpersonal 
approach treatment to take effect. The small number of drop-outs confirms the effectiveness of 
this approach. 
Aside from this difference in the anxiety reduction process between the combined and 
single approach treatment, common patterns were detected. Both treatment approaches decreased 
anxiety linearly. Also, quadratic trends were found for both approaches. The anxiety scores 
tapered offtowards the end ofthe sessions. This means that at that point, between sessions 10 
and 12, there were no more addition al therapeutic gains. As such, lOto 12 sessions are sufficient 
for either a combined or single treatment to engender therapeutic changes in participants. This is 
useful information for clinicians, because stretching out a treatment longer than those 10 to 12 
sessions will not continue benefiting the participant. Completely eliminating anxiety while in a 
social context is not realistic, not even for a non social phobic. There will invariably be a certain 
amount of anticipation when, for example, meeting someone for the first time. As long as that 
level of anxiety is tolerable and eventually dissipates somewhat, the individual is no longer 
incapacitated and unable to function. Therefore, since no therapeutic benefits will continue past 
that number of sessions, prolonging the treatment would not be advantageous for either the 
participants or the clinicians. 
As shown in this study, the interpersonal approach to therapy itself is anxiety provo king, 
which can seem counter-intuitive when treating a pattern of conduct that has anxiety as one of its 
core features. However, this treatment helps reduce anxiety by placing individuals continuously 
in anxiety evoking situations, while providing them with new strategies of conduct to replace the 
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overly defensive ones. During therapy, anxiety does increase several times for the participants 
because they face there very thing that distresses them. Nevertheless, over a short period of time 
(lOto 12 weeks), the overall experience of anxiety reduces significantly. AIso, by adding 
medication to this therapy, those temporary surges of anxiety are attenuated to allow greater 
therapeutic gains. 
Findings and SP Litera/ure 
The findings ofthis study show that anxiety 1S an important aspect ofimprovement in SP. 
Yet these results aiso show that it is not the only aspect of improvement as certain treatment 
frameworks posit. Therefore, just aiming to correct social skills or distorted thought processes in 
social phobics ignores other essential aspects ofSP. For example, CR ai ms at eroding 
maladaptive thoughts and reducing avoidant behaviours of the individual, and by doing so 
reducing social anxiety. Yet the effectiveness of the combined treatment and ev en the 
interpersonal approach treatment in this study show that on top ofbeing a state of anxiety, SP is 
also a combination of self-protective patterns. In addition, the results of this study support an 
interpersonal perspective ofSP, where social anxiety and social functioning exist and interplay 
between the individual and the social context (Stravynski, 2007, pp. 300). 
Contrary to exposure, CR and SST, the interpersonal approach to therapy can be seen as a 
two-pronged treatment that addresses both dimensions of improvement of SP: social functioning 
and anxiety. AIso, the interpersonal approach not only reduces avoidant behaviours but replaces 
defensive self-protective patterns with more adaptive ones as weIl, while the medication assuages 
the experience of anxiety in order for the social phobie individual to learn these new patterns 
without being incapacitated. 
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Despite being a simplistic and incomplete treatment on its own, the pharmacological 
approach, when combined with a psychological approach, does appear to have sorne merit based 
on the results of this study. The combination treatment of paroxetine and the interpersonal 
approach to therapy addresses social anxiety, avoidant behaviour and the defensive pattern 
simultaneously and consequently ensures greater chances of successfully completing treatment 
and replacing this pattern with more socially participatory ones. 
Strengths and Limitations 
As with all research, certain shortcomings exist in this study. Sample size for this study 
was adequate but a larger one would increase the validity of the results. Aiso by having a larger 
sample size, there would be a greater chance to have a more representative sample of the 
population. The participants in this study were mainly French-speaking and from a particular 
cultural background. Moreover, the sample ofthis study comprised of participants who actively 
sought out treatment as part of clinical research trial. Thus the results possess limited 
generalizability to primary care practices, where most social phobies seek treatment. 
The use of self-report questionnaires for measuring anxiety presents its own limitations. 
Participant bias, in terms ofmemory decay, can prevent accurate reporting the "true" state of 
anxiety. This type of questionnaire also relies on the respondents' ability to honestly deliver their 
level of distress; sorne participants might have possibly over- or under-exaggerated their 
experience of anxiety. Anxiety is a complex state to measure. It can be done objectively by 
measuring the physiologie al symptoms of anxiety (sweating, palpitations etc.) or by use of self-
reports. These self-report questionnaires, such as the ones used in this study, have valid 
psychometrie properties and despite the ever-existing risk ofparticipant bias in the responses, the 
use of these materials to measure anxiety is a reliable and valid method. However, the ecological 
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validity ofthese self-report measures, wh ether they accurately measure the real-life experience of 
anxiety, remains an open question that ought to be addressed. 
One unique advantage this study has is that it investigated the process of anxiety 
reduction rather than focusing exclusively on the outcome. As outlined in the beginning of this 
paper, there are not many process studies that have been conducted and none with a combination 
of SSRI and an interpersonal approach to therapy. Moreover, the use of trend analysis and the 
ca1culation of the effect size were not done in other process studies, leaving many unanswered 
questions about the process of anxiety reduction. In applying these analyses in this study, it was 
possible to discern the pattern in both conditions and compare them; thus elucidating a qualitative 
difference, on top of a quantitative difference. Therefore, this study provided much needed 
clarification of the process of anxiety reduction in the treatment of SP. 
AIso, research on the currently used class ofmedication for SP, SSRIs, combined with 
psychological treatment is far and few between. By examining the process of anxiety reduction of 
a combined treatment, this study adds valuable insight and knowledge into the way participants 
experience anxiety during treatment and which treatment better manages such a process. 
Practically, mental health parishioners would benefit from the findings ofthis study to determine 
the appropriate treatment for social phobics. 
Future Directions 
The use of paroxetine in combination with the interpersonal approach does help to reduce 
anxiety, but such a therapeutic change takes a certain period oftime to manifests itself during the 
treatment plan. Interpersonal approach to therapy in itself shows consistent indications ofbeing 
an effective treatment for reducing anxiety and improving social functioning. An earlier study by 
Stravynski et al. (2000) demonstrated equivalent and substantial improvements in social 
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functioning and di stress levels with the same treatment approach. Even with a low dropout rate, 
it would still be important to detennine ways to reduce it even more and ensure participants are 
comfortable in completing their treatment. For example, a future study could examine relaxation 
elements and the interpersonal approach and compare such a combination to the interpersonal 
approach to therapy alone to detect if it reduces anxiety to a greater degree. 
One such technique is the Abbreviated Progressive Muscle Relaxation Technique used in 
clinical and research settings (Carlson & Hoyle, 1993; Turner, Calhoun & Adams, 1992). This 
approach involves tensing and relaxing 16 different muscles groups. As such, participants 
practicing this technique would then learn to identify their anxiety and relax their muscles in a 
tense situation, thereby reducing their anxiety. If the combined treatment results in lower anxiety 
levels than the single approach, this would help clinicians better treat SP and the high levels of 
anxiety experienced during treatment. This potential approach would provide individuals and 
clinicians with a non-medication alternative to reduce anxiety. 
However, the nature of relaxation therapy to treat anxiety stems from an intrapersonal 
origin. From that point ofview, anxiety cornes from the individu al and their lack of skills in 
managing it. Relaxation techniques train the individual in recognizing and dealing with their 
anxiety symptoms. Yet as we've seen, SP is a social pattern that subsists in a social context. 
Therefore j ust training a person in relaxation does not address the social nature of anxiety for SP. 
An alternative treatment ifmedication or relaxation is not appropriate would be to 
implement exposure elements in the interpersonal approach. Since exposure is a well-
documented treatment for anxiety, highlighting such an approach would presumably reduce 
anxiety to a greater degree. This could be done by introducing more "reallife" exposure 
situations and increasing the ecological validity of the study. In the interpersonal approach to 
therapy sessions, participants are exposed to their feared spheres of social functioning in session 
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with other pmiicipants and the clinician. Although it is a social context, it is still a somewhat 
artificial setting since it is in a clinic office and the participants are not actual coworkers, 
managers, romantic interests etc. AIso, wh en asked to apply the leamed techniques in their actual 
life situations, it is possible sorne participants wou Id avoid that task and not face and conquer 
their social anxiety. 
To make the exposure elements more "realistic", clinicians could organize actual 
presentations, parties with non-social phobics and have the participants actively engage in these 
activities. That way, the participants would be obligated to face their anxiety and overcome it by 
participating less artificial situations. This "reallife" interpersonal approach to therapy would 
hypothetically diminish anxiety more so than the traditional version. Research could use 
observation techniques to measure quantifiable signs of anxiety during the activities to use 
conjointly with self-report questionnaires and bolster the strength oftheir measures. 
As a final note, the effectiveness of the combination treatment in this study counters 
Stravynski' s conclusions on his review of outcome studies. He found that combination treatments 
were not any more effective at reducing anxiety than purely psychological treatments. In this 
study however, the combination treatment had greater success than the interpersonal approach 
treatment at reducing anxiety after 12 sessions. Although this is one study compared to an 
exhaustive review, the results put into question his conclusion and invites further combination 
treatment studies to be conducted to clarify this discrepancy. 
Consequently, a much greater number combination studies of SSRls and psychotherapies 
are required. Furthermore, a comparison of an interpersonal approach with an existing and well-
established treatment of anxiety (exposure) would serve as a benchmark. Ideally, such study 
would also have a larger and more representative sample, including participants of different 
language backgrounds and ethnicities. Finally, different combination ofpsychotherapy and 
phannacology would provide new insights. Either using an interpersonal approach to therapy 
before or after medication in an experimental design is yet to be tried. 
64 
References 
American Psychiatrie Association. (1994). Diagnostic and Statistical Manual of Mental 
Disorders, (4th edition), Washington, DC: APA. 
Asakura, S., Tajima. O., & Koyama, T. (2007). Fluoxamine treatment of generalized social 
anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. 
International Journal ofNeuropsychopharmacology, 10: 263-274. 
Atmaca, M., Kulogl0, M., Tezcan, E., & Unal, A. (2002). Efficacy of citalopram and 
moclobemide in patients with social phobia: Sorne preliminary findings. Human 
Psychopharmacology & Clinical Experience, 17: 401-405. 
Beek, A.T. (1976). Cognitive therapy & the emotional disorders. NY: International University 
Press. 
Bellino, S., Zizza, M., Rinaldi, c., & Bogetto, F. (2006). Combined treatment of major 
depression in patients with borderline personality disorders: A comparison with 
pharmacotherapy. Canadian Journal of Psychiatry, 51 (7): 453-460. 
Blanchard, E.B., Gerardi, R. J., Kolb, L.C., & Barlow, D. H. (1986). The utility of the 
Anxiety Disorders Interview Schedule (ADIS) in the diagnosis of the Post-traumatic 
Stress Disorder (PTSD) in Vietnam veterans. Behaviour Research and Therapy. 24(5): 
577-580. 
Bogels, S.M., Sijbers, G.F.V.M., Voncken, M. (2006). Mindfulness and task 
concentration training for social phobia: A pilot study. Journal of Cognitive 
Psychotherapy, 20(1): 33-44. 
Bouchard, S., Gauthier, l, Laberge, B., French, D., Pelletier, M.H., & Godbout, C. (1996). 
Exposure versus cognitive restructuring in the treatment of panic disorder with 
agoraphobia. Behaviour Research & Therapy, 34(3): 213-214. 
65 
Bournan, T.K., & de Ruiter, C. (1991). The validity of the Anxiety Disorders Interview 
Schedule--Revised (ADIS--R): A pilot study. Gedragstherapie. Vol 24(2) : 77-78. 
Carlson, C. R., & Hoyle, R. H. (1993). Efficacy of abbreviated progressive muscle relaxation 
training: A quantitative review ofbehavioral medicine research. Journal of Consulting 
and Clinical Psychology, 61, 1059-1067. 
66 
Clark, D.M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., 
Davenport, C., & Louis, B. (2003). Cognitive therapy versus fluoxetine in generalized 
social phobia: A randomized placebo-controlled trial. Journal of Consulting and Clinical 
Psychology, 71: 1058-1067. 
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: 
Lawrence Earlbaum Associates. 
Cottraux, J., Note, L, Yoa, S.N., Lafont, S., Mollard, E., Bouvard, M., Sauteraud, A., Bourgeois, 
M., & Dartigues, J.F. (2001). A randomized controlled trial of cognitive therapy versus 
intensive behaviour therapy in obsessive compulsive disorder. Psychotherapy & 
Psychosomatics, 70(6): 288-297. 
Cottraux, l, Note, L, Albuisson, E., Yao, S.N., Note, B., Mollard, E., Bonasse, F., Jalenques, L, 
Guérin, J., & Coudert, A.l (2000). Cognitive behaviour therapy versus supportive therapy 
in social phobia: A randomized controlled trial. Psychotherapy & Psychosomatics, 69: 
137-146. 
Cox, B.l, Swinson, R.P., & Shaw, B.F. (1991). Value ofthe Fear Questionnaire in differentiating 
agoraphobia and social phobia. British Journal of Psychiatry, 159: 842-5. 
67 
Davidson, J.RT., Foa, E.B., Huppert, lD., Keefe, F.l, Franklin, M.E., Compton, lS., Zhao, N., 
Connor, KM., Lynch, T.R., & Gaddle, K.M. (2004a). Fluoxetine, comprehensive 
behavioural therapy and placebo in generalized social phobia. Archives of General 
Psychiatry, 61: 1005-1013. 
Davidson, J.RT., Yaryuar-Tobias, J., DuPont, R, Stallings, L., Barbato, L.M., van der Hoop, 
RG., & Li, D. (2004b). Fluoxamine-controlled release formulation for the treatment of 
generalized social anxiety disorder. Journal of Clinical Psychopharmacology, 24: 118-
125. 
di Nardo, P.A., Moras, K, Barlow, D. H., Rapee, R M., & Brown T. A. (1993). Reliability 
ofDSM-III-R anxiety disorder categories using the Anxiety Disorder Interview Schedule-
Revised (ADIS-R). Archives of General Psychiatry, 50(4):251-256. 
Foa, E.B., Liebowitz, M.R, Kozak, M.J., Davies, S., Campeas, R, Franklin, M.E., Huppert, J.D., 
Kjernisted, K, Rowan, V., Schmidt, A.B., Simpson, H.B., & Tu, X. (2005). Randomized, 
placebo-controlled trial of exposure and ritual prevention, clomipramine, and their 
combination in the treatment of obsessive-compulsive disorder. American Journal of 
Psychiatry, 162(1): 151-16l. 
Heimberg, R.G., Liebowitz, M.R., Hope, D.A., Schneier, F.R, HoIt, C.S., Welkowitz, L.A, 
Juster, H.R, Campeas, R., Bruch, M.A., Cloitre, M., Fallon, B., & Klein, D.F. (1998). 
Cognitive behavioural group therapy vs. phenelzine therapy for social phobia: 12-week 
outcome. Archives of General Psychiatry, 55: 1133-114l. 
Lee, H.B & Oei, T.P.S. (1994). Factor structure, validity, and reliability of the 
Fear Questionnaire in a Hong Kong Chinese population. Journal of Psychopathology 
and Behavioral Assessment, 16(3): 189-199. 
.68 
Lepola, u., Bergtholdt, B., Lambert, 1., Davy, K.L., & Ruggiero, L. (2004). Controlled release 
paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical 
Psychiatry, 65: 222-229. 
Liebowitz, M.R, Mangano, RM., Bradwejn, 1., & Asnis, G. (2005). A randomized controlled 
trial of venlafaxine extended release in generalized social anxiety disorder. Journal of 
Clinical Psychiatry, 66: 238-247. 
Liebowitz, M.R, DeMartinis, N.A., Weihs, K., Londborg, P.D., Smith, W.T., Chung, H., Fayyad, 
R., & Clary, C.M. (2003). Efficacy of sertraline in severe generalized social anxiety 
disorder: Results of a double-blind, placebo-controlled study. Journal of Clinical 
Psychiatry, 64: 785-792. 
Liebowitz, M.R, Stein, M.B., Tancer, M., Carpenter, D., Oakes, R., & Pitts, CD. (2002). A 
randomized, double-blind, fixed-dose comparison ofparoxetine and placebo in the 
treatment of generalized social anxiety disorder. Journal ofClinical Psychiatry, 63: 66-
74. 
Marks, L, Lovell, K., Noshirvani, H., Livanou, M. & Thrasher, S. (1998). Treatment of post-
traumatic stress disorder by exposure andlor cognitive restructuring. Archives of General 
Psychiatry, 55: 317-325. 
Marks, LM., Swinson, RP., Basoglu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliott, P.T., 
Kirby, McNamee, M., Seguin, S. & Wickwire, K. (1993). Alprazolam and exposure alone 
and combined in panic disorder with agoraphobia: A controlled study in London and 
Toronto. British Journal of Psychiatry, 162: 776-787. 
Marks, LM. (1987). Fears, phobias and rituals. NY: Oxford University Press. 
Marks, 1. M., & Matthews, A. N. (1979) Brief standard self-rating for phobic patients. 
Behavior Research and Therapy, 17(3),263-267. 
69 
Mavissakalian, M (1986). The fear questionnaire: A validity study. Behaviour Research and 
Therapy, 24 (1): 8883-85. 
Moylan, A & Oei, T.P.S. (1992). 1s the Fear Questionnaire (FQ) a useful instrument for 
patients with anxiety disorders? Behaviour Change, 9, 38-49. 
Noyes, R, Moroz, G., Davidson, J.R, Liebowitz, M.R., Davidson, A, & Siegel, J. (1997). 
Moc1obemide in social phobia: A controlled dose-response trial. Journal of Clinical 
Psychopharmacology, 17: 247-254. 
Oei, T.P.S., Kenna, D., & Evans, L. (1991). The reliability, validity and utility of the SAD 
and FNE scales for anxiety disorders patients. Personality & lndividual Differences, 
12,111-116. 
Osman, A Barrios, F X. Osman, J R. Markway, K. (1993). Further psychometrie evaluation 
of the Fear Questionnaire: responses of college students. Psychological Reports, 73(3 Pt 
2): 1259-66. 
Otto, M.W., Pollack, M.H., Gould, RA, Worthington, J.J., McArdle, E.T., & Rosenbaum, J.F. 
(2000). A comparison of the efficacy of c10nazepam and cognitive-behavioural group 
therapy for the treatment of social phobia. Journal of Anxiety Disorders, 14: 345-358. 
Pande, AC., Feltner, D.E., Jefferson, J.W., Davidson, J.R.T., Pollack, M., & Stein, M.B. (2004). 
Efficacy ofnovel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, 
multicenter study. Journal ofClinical Psychopharmacology, 24: 141-149. 
Pande, AC., Davidson, J.R.T., Jefferson, J.W., Janney, C.A., Katzelnick, DJ., Weisler, RH., 
Greist, J.H., & Sutherland, S.M. (1999). Treatment of social phobia with gabapentin: A 
placebo-controlled study. Journal ofClinical Psychopharmacology, 19: 341-348. 
70 
Prasko, J., Dockery, C., Horacek, l, Houbova, P., Kosova, l, Klaschka, J., Paskova, B., 
Praskova, H., Seifertova, D., Zalesky, R, & Hoschl, C. (2006). Moclobemide and 
cognitive behavioural therapy in the treatment of social phobia. Neuroendocrinology, 24 
(4): 473-481. 
Rickels, K., Mangano, R, & Khan, A (2004). A double-blind, placebo-controlled study of a 
flexible dose ofvenlafaxine ER in adults outpatients with generalized social anxiety 
disorder. Journal of Clinical Psychopharmacology, 24: 488-496. 
Sarason, B. (2007). Abnormal Psychology. ]'N : Prentice Hall. 
Scholing, A, & Emmelkamp, P.M.G. (1993). Exposure with and without cognitive therapy for 
generalized social phobia: Effects of individual and group treatment. Behaviour Research 
& Therapy, 31: 667-681. 
Scott, E.L., & Heimberg, RG. (2000). Social Phobia: An update on treatment. Psychiatrie 
Annals, 30(1): 678-686. 
Seedat, S., & Stein, M.B. (2004). Double-blind, placebo-controlled assessment of combined 
clonazepram with paroxetine compared with paroxetine monotherapy for generalized 
social anxiety disorder. Journal of Clinical Psychiatry, 65: 244-248. 
Sharp, D. M., Power, K. G., Simpson, R J., Swanson, V, Moodie, E., Anstee, J. A., & 
Ashford, l l (1996). Fluvoxamine, placebo, and cognitive behavior therapy used alone 
and in combination in the treatment of panic disorder and agoraphobia. Journal of Anxiety 
Disorders, 10: 219-242. 
Stein, DJ., Cameron, A, Amrein, R, & Montgomery, S.A (2002). Moc1obemide is effective and 
well-tolerated in the long-term pharmacotherapy of social anxiety disorder with and 
without comorbid anxiety disorder. International Clinical Psychopharmacology, 17: 161-
170. 
Stein, M.B., & Kean, Y (2000). Disability and quality oflife in social phobia: Epidemiological 
findings. American Journal ofPsychiatry, 157: 1606-1613. 
Stein, M.B., Fyer, Al, Davidson, J.RT., Pollack, M.H., & Wiita, B. (1999). Fluoxamine 
treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled 
study. American Journal of Psychiatry, 156: 756-760. 
Stravynski, A (2007). Fearing others: The nature and treatment ofsocial phobia. Cambridge, 
UK: Cambridge Unversity Press. 
71 
Stravynski, A, Arbel, N., Chenier, N., Lachance, L., Lamontagne, Y, Sidoun, P., & Todorov, C. 
(2006). Treating social phobia interpersonally: Dismantling the ingredients of a 
behavioural approach (submitted for publication). 
Stravynski, A., Arbel. N., Bounader, J., Lachance, L., Borgeat, F., Lamontagne, Y, Sidoun, P., & 
Todorov, C. (2000). Social phobia treated as a problem functioning: a controlled 
comparison oftwo behavioural group approaches. Acta Psychiatrica Scandinavica, 102: 
188-198. 
Stravynski, A, Grey, S., & Elie, R (1987). Outline of the therapeutic process in social skills 
training with socially dysfunctional patients. Journal of Consulting and Clinical 
Psychology, 55: 224-228. 
Turner, S.M., Calhoun, K. S., & Adams, H. E. (Eds.) (1992). Handbook ofClinical Behavior 
Therapy. New Yorle Wiley. 
van Amerigen, M., Lane, RM., Walker, J.R, Bowen, RC., Chokka, P.R, Goldner, E.M., 
Johnston, D.G., Lavallé, YJ., Nandy, S., Pecknold, J.C., Hadrava, V., & Swinson, RP. 
(2001). Sertraline treatment of generalized social phobia: A 20-week, double-blind, 
placebo-controlled study. American Journal ofPsychiatry, 158: 275-281. 
72 
van Oppen, P., de Haan, E., van Balkom, AJ.L.M., Spinhoven, P., Hoogduin, K. & van Dyck, R. 
(1995). Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive 
disorder. Behaviour Research & Therapy, 33(4): 379-390. 
van Vliet, LM., de Boer, lA, & Westenberg, H.G.M. (1994). Psychopharmacological treatment 
of social phobia: A double blind placebo controlled study with fluoxamine. 
Psychopharmacology, 115: 128-134. 
van Zuuren, FJ. (1988). The fear questionnaire. Sorne data on validity, reliability and layout. 
British Journal ofPsychiatry, 153:659-62. 
Versiani, M., Nardi, AE., Mudim, F.D., Alves, AB., Liebowitz, M.R., & Arnrein, R. (1992). 
Pharmacotherapy of social phobia: A controlled study with moc1obemide and phenelzine. 
British Journal of Psychiatry, 161: 353-360. 
Watson, D., & Friend, R. (1969). Measurement of social-evaluative anxiety. 
Journal of consulting and clinical psych0 logy, 33(4),448-457. 
Westerberg, H.G.M., Stein, D.J., Yang, H., Li, D., & Barbato, L.M. (2004). A double-blind 
placebo-controlled study of controlled release of fluvoxamine for the treatment of 
generalized social anxiety disorder. Journal ofClinical Psychopharmacology, 24: 49-55. 
Yonkers, K.A, Dyck, LR., M.P.H. Keller, M.B. (2001).An Eight-Year Longitudinal Comparison 
ofClinical Course and Characteristics of Social Phobia Arnong Men and Women. 
Psychiatrie Services, 52:637-643 
Xll 
Appendix 1: Telephone interview script 
PHONE INTERVIEW DATE: ______ _ 
FAMILY NAME: ______ _ FIRST NAME: ________ _ 
DIAGNOSTIC: SOCIAL PHOBIA: __ _ OTHER: _____ _ 
NAME OF THE INTERVIEWER: _______________ _ 
1) DO YOU T AKE ANY MEDICATION? YES __ _ NO __ _ 
Ifyes, what kind? ___________________ _ 
2) HOW MUCH ALCOHOL DO YOU CONSUME? 
Weekly? Daily? _____ _ 
3) PRESENTLY, DO YOU FE EL DEPRESSED, BLUE, WITH NO ENERGY? 
YES ___ _ NO ___ _ 
4) WHICH SOCIAL SITUATIONS ARE DIFFICULT FOR YOU? _______ _ 
5) WHAT IS THE IMPACT OF THESE DIFFICULTIES ON YOUR EVERYDAY 
LIFE? 
-------------------------------
Have you ever been scared or have you ever avoided: 
Scared Avoided 
Yes No Yes No 
a) Speaking in public 
b) Writing in public 
c) Eating/drinking in public 
d) Working under obs. 
e) Urinating in public 
f) Going to a party 
g) Initiating a conversation 
h) Interacting with opp. Sex 
i) Addressing authority 
j) Talking on the phone 
Comments 
Intensity/frequency 
X111 
6) HAVE YOD EV ER CONTACTED A HEALTH PROFESSIONAL FOR A PHYSICAL OR 
MENTALPROBLEM? 
YES _____ _ NO ______ _ 
If yes, explain: 
What were the diagnostics and the treatments?: 
AV AILABILITY 
A.M. 
P.M. 
EVENIl\JG (5-7PM) 
EVENING (7-9PM) 
MAKE SURE THAT THE PERSON REPEATS AND SPELLS THE 
SOCIO-DEMOGRAPHIC II\IFORMATION 
FAMILY NAME: ________ FIRST NAME: _____ _ 
ADDRESS: Street 
--------------------
City: _______ _ Postal code: 
-------
PHONE NUMBER: Home: _______ _ Work: 
------
How did you hear about us? 
Web Pamphlet Another person Other 
-----
Any other problems that you forgot to mention? ________ _ 
Appendix II: SAD 
Social Anxiety And Distress (SAD) 
Please respond by TRUE (1) or FALSE (2) to each of the following sentences. Indicate 
your answer that corresponds to your actual state. 
1. 1 feel relaxed even in unfamiliar social situations. 
2. l try to avoid situations which force me to be very sociable. 
3. It is easy for me to relax when 1 am with strangers. 
4. 1 have no particular desire to avoid people. 
5. 1 often find social situations upsetting. 
6. 1 usually feel calm and comfortable at social occasions. 
7. l am usually at ease when talking to someone of the opposite sex. 
8. 1 try to avoid talking to people unless 1 know them well. 
9. If the chance cornes to meet new people, 1 often take it. 
10. 1 often feel nervous or tense in casual get-togethers in which 
both sexes are present. 
II. 1 am usually nervous with people unless 1 know them weIl. 
12. 1 usually feel relaxed when 1 am with a group of people. 
13.1 often want to get away from people. 
14.1 usually feel uncomfortable when 1 am with a group ofpeople 
1 don't know. 
15. 1 usually feel relaxed when 1 meet someone for the first time. 
16. Being introduced to people makes me tense and nervous. 
17. Even though a room is full of strangers, 1 may enter it anyway. 
18. 1 would avoid walking up and joining a large group of people. 
19. When my superiors want to talk with me, 1 talk willingly. 
A 
A 
A 
A 
A 
A 
XIV 
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20. l often feel on the edge when l am with a group of people. A 
21. l tend to withdraw from people. A 
22. l don't mind talking to people at parties or social gatherings A 
23. l am seldom at ease in a large group of people. A 
24. l often think up excuses in order to avoid social engagements. A 
25. l sometimes take the responsibility for introducing people to each other. A 
26. l try to avoid fonnal social gatherings. A 
27. l usually go to whatever social engagement l have. A 
28. l find it easy to relax with other people. A 
XVI 
Appendix III: FQ 
FEAR QUESTIONNAIRE (FQ) 
Choose a number from the scale below to show how much you would avoid each of the situations 
listed below because of fear or other unpleasant feelings. Then write the number you chose in the 
box opposite to each situation 
o 1 2 3 4 
Would not 
avoid it 
Slightly 
avoid it 
# Question 
1 Injections or minor surgery 
2 Eating or drinking with other people 
3 Hospitals 
4 Travelling alone by bus or coach 
5 Walking alone in busy streets 
6 Being watched or stared at 
7 Going into crowded shops 
8 Talking to people in authority 
9 Sight ofblood 
10 Being criticized 
11 Going alone far from home 
12 Thought of injury or illness 
13 Speaking or acting to an audience 
14 Large open spaces 
15 Going to the dentist 
5 
Definitely 
avoid it 
6 
Markedly 
avoid it 
7 8 
Always 
avoid it 
1 to 8 
Bow choose a number from the scale below to show how much you are troubled by each problem 
listed, and write the number in the box opposite 
o 1 2 3 
Hardly 
at a11 
Slightly 
disturbing 
# Questions 
16 Feeling miserable or depressed 
17 Feeling irritable or angry 
18 Feeling tense or panicky 
4 
Definitely 
disturbing 
19 Upsetting thoughts coming into your mind 
5 
20 Feeling you or your surroundings are strange or unreal 
6 7 
Markedly 
disturbing 
8 
Very 
severely disturbing 
1 to 8 
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Appendix IV: Consent [onu 
TITLE : The treatment of social phobia with the combination of interpersonal therapy and paroxetine 
Researchers: Dr Ariel Stravynski, Ph.D. and Dr Paul Sidoun, M.D. 
Contact: Danielle Amado, M.Ps. 
TREATMENT OF SOCIAL PHOBIA 
Mr,Ms, ____________________________________________ __ 
You have been selected to participate in a study that aims to compare the efficacy of several types of 
treatment of social phobia. However, before signing the consent form, it is important that you attentively read 
the following information and that you ask questions in order to fully understand what your participation 
involves. 
Dr Ariel Stravynski and Danielle Amado, psychologists, supervise this study. 
PROJECT DESCRIPTION 
Social phobia is a persistent fear of one or many situations in which one is likely to be observed fearing of 
acting in a way that would feel humiliating or embarrassing (examples: being afraid of speaking in public, 
of choking while eating with others, shaking while writing). Generally, people who have this problem have 
a tendency to forsee dangers and catastrophes in certain social situations. They tend to use avoidance 
strategies so as not to confront these situations and to minimize feelings of anxiety. Such tendency 
contributes to maintaining this problem. 
This program aims to decrease anxious distress by bringing the person to confront anxiety-provoking 
situations and thereby diminish the avoidance that occurs in these situations. 
Specifically, the goal of this study is to assess whether the combination of a medication with an interpersonal 
kind of psychotherapy will result in a better outcome than each of these treatments administered separately. 
The efficacy of the medication as weil as the psychotherapy have already been documented in previous 
studies. The purpose of the present study is to assess what remains unknown, that is, the effect of their 
combination. 
The psychological approach consists in teaching the participant to confront systematically situations that 
evoke anxiety while using new ways of behaving in those situations. The pharmacological approach 
consists of receiving a prescription of Paxil (generic name: paroxetine). It is a selective serotonin 
reuptake inhibitor (SSRI) anti-depressant that acts as a specifie inhibitor to serotonin and contributes to a 
better regularization of this neurotransmitter. The medication aims at controlling and diminishing anxious 
distress and the desire to avoid or run away from anxiety provoking situations. The anticipated doses are 
10 to 50 mg/day to reach a maximum efficacy and a optimal tolerability. This treatment will be held 
individually with a psychiatrist that will supervise the administration of the medication and the dosage 
during the 12 weeks of the active treatment. 
The psychotherapy will involve small groups of 5 to 6 participants. This situation in itself may generate 
anxiety and apprehension for some. But, facing this situation repeatedly, is beneficial in itself. Also, during 
group meetings and between sessions, we ask that each participant performs certain tasks that might 
momentarily generate anxiety: for example, if a participant feels anxious when writing while being 
observed, we may ask him to perform that task; if another is afraid that people will notice he is blushing, 
he may have to do a brief presentation, etc. 
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PROCEDURES 
You are presently accepted in the treatment program for social phobia. Your commitments are the 
following: 
1.: Assessments: 1 will participate in an interview with a psychiatrist (1 hour), in 4 assessments with a 
psychologist (1 h30) after which 1 will have to fill out different computerized questionnaires (1 h). 
These assessment sessions will take place at 4 times: before and after treatment, 6 months and 1 
year after the end of treatment. 
2- Treatment: 1 will participate in 5 individual meetings of pharmacotherapy spread through the 12 
weeks, as weil as a meeting that will take place 3 months after the end of the sessions. 1 commit 
myself to participate in 12 weekly meetings in small groups of 5-6 people for a duration of 2 hours 
each, as weil as to a meeting that will take place 3 months after the end of treatment. Also, 1 
commit myself to carry out some homework tasks of self-observation as weil as fill out two 
questionnaires on several occasions. Finally, 1 commit myself to carry out in between the sessions 
various specific assignments that will be given me by the therapist (example: initiating a 
conversation or as king for information to a stranger). 
While participating in this program, 1 am aware that 1 cannot be involved in any other type of 
therapy, nor take psychotropic drugs. Also, 1 understand that 1 cannot drink alcohol in order to 
diminish or control the anxiety that 1 may feel in certain social situations. These instructions are 
valid for the duration of the treatment and the follow-ups, meaning one year after the end of 
treatment. 1 understand that 1 should inform the researcher and quit the study if 1 do not respect 
these conditions. Furthermore, the researcher has the right to suspend my participation in the 
program if 1 do not respect these conditions. 
INCONVENIENTS AND RISKS 
The possible side effects of paroxetine are the following (in order of probability): headaches, fatigue, 
palpitations, hypotension, sweating, nausea, dry mouth, constipation, diarrhea, increase of appetite, 
somnolence, insomnia, trembling, nervousness, reduction of libido, yawning, vision problems, sexual 
dysfunction, psychosis and allergic reaction, especially to hypersensitive individuals. However, you will be 
closely monitored during the administration of the medication. This will be done gradually and the side 
effects will be taken to account during the treatment. 
For the termination of the medication, the possible side effects are nausea, diziness, fatigue and an increase 
of anxiety. You will receive consultations and will be monitored by members of the therapy team during this 
period. 
The homework assignments can at first provoke a certain degree of anxiety that will normally subside with 
time. The level of anxiety is generally similar to the one that may be experienced when people expose 
themselves to such situations in their natural environ ment. 
Alternative treatments for social phobia exist and they involve psychopharmacology such as 
(Benzodiazepines and anti-depressors IMAO) or psychotherapy (exposition, cognitive therapy). 
ADVANTAGES ET BENEFITS 
The advantages that you can expect are a reduction of your anxious state, a weaker tendency to avoid 
social situations and a better participation in sociallife. 
WITHDRAWAL FROM THE STUDY 
We reserve the right to remove you from the study, without your consent, for the following reasons: 
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a) Your physical or psychological state needs a more appropriate alternative treatment; you will 
be then referred to the appropriate services. 
b) You refuse to follow the instructions mentioned above. 
However. your participation in this study is fully voluntary and you may interrupt the process at any 
given time. 
CONFIDENTIAUTY 
The team members have taken different measures to insure the greatest confidentiality: 
- Files are kept in locked cabinets which are in an office assigned especially for this study; 
- The assignment of subject numbers preserve the anonymity of the collected information; 
- The use of a password in order to access computerized information. 
uterized information is reserved in an anon ous data bank for an unlimited amount of time. 
FREEDOM TO PARTICIPATE IN OR WITHDRAW FROM THE STUDY 
If you decide, by your own will, to dropout from the study, this will not cause you any prejudice 
and will not hinder your right to receive adequate treatment for your difficulties. 
PERSON TO CONTACT 
If you feel any worries related to your participation, you can reach Danielle Amado directly at 
(514) 251-4015, extension 2347. 
1 therefore consent to participate in a psychological treatment for social phobia. 1 recognize that 1 
have been informed of the program's procedure and the fees that 1 will have to pay. 
ln accepting to participate in this study, 1 do not renounce any of my rights and 1 do not free the 
researchers. organizations. companies or ail implicated institutions of their legal and professional 
responsibilities. 
Signatures: of participant: _____________ _ 
ofwitness: 
1 certify that a) 1 explained the terms and conditions of the present consent form to the participant signing this 
document b) 1 answered the questions that were asked regarding this consent form; c) 1 clearly indicated that 
he/she is free to dropout of the study at any time; and d) 1 will provide him/her a copy of the present signed 
consent form. 
Name of researcher or 
authorized representative 
Function Signature Date 
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Appendix V: Paroxetine administration protocol table 
Week Session Content 
0 0 Inclusion, wash out period 
1 1 Introduction of medication (10-20 mg) 
2 2 Evaluation, monitoring of side effects; increase (30 mg) 
6 3 Evaluation, monitoring of side effects; increase (40 mg) 
10 4 Evaluation, monitoring of side effects; increase (50 mg) 
12 5 Evaluation and stopping medication (dosage gradually decreasing 
24 6 Evaluation, listing of symptoms; related to the stopping of medication 
36 7 Evaluation, listing of symptoms; related to the stopping of medication 
Appendix VI: Pairwise comparisons 
Table XI. Significant pairwise comparisons oftime for the SAD total scores of the 
sample. 
Time Statistics 
Mean Difference 
Beginning of treatment Session 1 
Beginning of treatment ns 
Session 1 
Session 2 
Session 6 
Session 10 
Session 12 
ns 
6.68*** 
10.78*** 
11.40*** 
13.28*** 
Note: ns (not significant); * p :::;.05; ** p :::;.01; 
*** P :::;.001 
5.04** 
9.13*** 
9.75*** 
11.64*** 
Session 2 
-6.68*** 
-5.04** 
4.09** 
4.71 *** 
6.60*** 
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Table XII. Significant pairwise comparisons oftime for the SAD Avoidance scores of the 
sample. 
Time Statistics 
Mean D(fJerence 
Beginning of treatment Session 1 Session 2 
Beginning of treatment 
Session 1 
Session 2 
Session 6 
Session 10 
Session 12 
2.02* 
2.75*** 
3.06* 
5.46*** 
6.42*** 
Note: ns (not significant); * p :S::.05; ** P :S::.01; 
*** P :S::.OOI 
-2.02* 
ns 
ns 
3.44** 
4.40*** 
-2.75*** 
ns 
ns 
2.71 *** 
3.67*** 
Session 6 
-3.06* 
ns 
ns 
2.40* 
3.35*** 
XXl1 
Table XIII. Significant pairwise comparisons oftime for the SAD Distress scores of 
the sample. 
Time Statistics 
Mean Difference 
Beginning of treatment 
Beginning oftreatment 
Session 1 2.40* 
Session 2 3.31 *** 
Session 6 7.04*** 
Session 10 5.35*** 
Session 12 6.31 *** 
Note: ns (not significant); * p =::;.05; ** p =::; 
.01; *** P =::;.001 
Session 1 
-2.40* 
ns 
5.04** 
9.13*** 
9.75*** 
Session 2 
-3.31 *** 
ns 
3.73*** 
2.04* 
3.00* 
XXlll 
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Table XIV. Significant pairwise comparisons of time for the FQ Composite scores of the 
sample. 
Time 
Beginning of treatment 
Beginnil1g of 
treatment 
Session 1 ns 
Session 2 2.44* 
Session 6 6.39*** 
Session 10 8.08*** 
Session 12 8.08*** 
Note: I1S (not significant); * p s.05; ** p s.Ol; 
*** p :=;;.001 
Statistics 
Mean Difference 
Session 1 Session 2 
ns -2.44* 
ns 
ns 
4.13** 3.95** 
5.81 *** 5.63*** 
5.81 *** 5.63*** 
Table XV. Significant pairwise comparisons oftime for the FQ Social Phobia scores of 
the sample. 
Time 
Beginning of treatment 
Session 1 
Session 2 
Session 6 
Session 10 
Session 12 
Beginning oftreatment 
ns 
ns 
6.18** 
7.53** 
7.53*** 
Note: ns (not significant); * p ~.05; ** p ~.01; 
*** p ~.001 
Statistics 
Mean Difference 
Session 1 Session 2 
ns ns 
ns 
ns 
4.41 * 4.08* 
5.76*** 5.43*** 
5.76** 5.43*** 
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Table XVI. Significant pairwise comparisons of time for the FQ Emotional Distress 
scores of the sample. 
Time Statistics 
Beginning of treatment Session 1 Session 2 
Beginning of treatment ns -4.71 ** 
Session 1 ns ns 
Session 2 4.71 ** ns ns 
Session 6 6.20** ns 
Session 10 8.88*** 6.17** ns 
Session 12 8.88*** 6.17** ns 
Note: ns * p < 05; ** p ::;.01; *** p 
::;.001 
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Appendix VII: Trend analysis tables 
Table XVII. Statistical significance oflinear trend analysis across time and 
treatment group. 
Statistics 
F 
Time GXT 
SAD: Total 225.71 *** 14.17*** 
SAD: A voidance 145.32*** 7.00** 
SAD: Distress 97.50*** 12.66*** 
FQ: Composite 67.10*** 4.58* 
FQ: Social Phobia 67.10*** 4.58* 
FQ: Emotional Distress 35.59*** 0.91 
* P :::;.05; ** P :::;.01; *** P :::;.001 
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Table XVIII. Statistical significance of quadratic trend analysis across time and 
treatment group. 
Statistics 
F 
Time GXT 
SAD: Total 4.98* 3.05 
SAD: Avoidance 0.12 0.12 
SAD: Distress 17.17*** 7.25** 
FQ: Composite 1.36 1.00 
FQ: Social Phobia 1.36 1.01 
FQ: Emotional Distress 2.09 0.40 
* P ~.05; ** P ~.01; *** P ~.001 
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Table XIX. Statistical significance of cubic trend analysis across time and treatment group. 
Statistics 
F 
Time GXT 
SAD: Total 3.72 9.78** 
SAD: Avoidance 3.05 6.52* 
SAD: Distress 0.51 12.85*** 
FQ: Composite 4.96* 1.63 
FQ: Social Phobia 4.96* 1.63 
FQ: Emotional Distress 0.22 0.17 
* p ::;.05; ** p ::;.01; *** P ::;.001 
xxx 
Appendix VIII: Sample trend graphs 
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Figure 9. Sample linear trend graph. 
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Figure 10. Sample quadratic trend graph. 
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Figure 11. Sample cubic trend graph 
